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ABSTRACT 
 
The first part of this work induced T-cell lymphoma in mice by employing a breeding 
scheme involving mouse strains expressing the KrasG12D oncoprotein and mice expressing 
cyclic recombinase from the mouse mammary tumor virus promoter. Imprinted domains were 
then systematically surveyed for DNA methylation changes during tumor progression using 
combined bisulfite restriction analysis and next-generation-bisulfite-sequencing. Hyper-or 
hypomethylation was detected at the imprinting control regions (ICRs) of the Dlk1, Peg10, Peg3, 
Grb10 and Gnas domains. These DNA methylation changes at ICRs were more prevalent and 
consistent than those observed at the promoter regions of well-known tumor suppressors, such as 
Mgmt, Fhit and Mlh1. Thus, the changes observed at these imprinted domains are the outcome of 
isolated incidents affecting DNA methylation settings. Within imprinted domains, DNA 
methylation changes tend to be restricted to ICRs as nearby somatic differentially methylated 
regions and promoter regions experience no change. Furthermore, detailed analyses revealed that 
small cis-regulatory elements within ICRs tend to be resistant to DNA methylation changes, 
suggesting potential protection by unknown trans-factors.   
The second part of this work further characterized the epigenetic response of imprinted 
domains during carcinogenesis. This study compared the stability of DNA methylation at a 
variety of cis-regulatory elements within imprinted domains in two fundamentally different 
mouse tumors, benign and malignant. The data suggest that imprinted domains remain quite 
stable in benign processes, but are highly susceptible to epigenetic alterations in infiltrative 
lesions. The preservation of DNA methylation within imprinted domains in benign tumors 
throughout their duration suggests that imprinted genes are not involved with the initiation of 
carcinogenesis or the growth of tumors. However, the frequent detection of DNA methylation 
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changes at imprinting control regions in infiltrative lesions suggest that imprinted genes are 
associated with tumor cells that have gained the ability to defy tissue boundaries.  
Overall, this study demonstrates that imprinted domains are targeted for DNA 
hypermethylation when benign tumor cells transition to malignant. Thus, monitoring DNA 
methylation within imprinted domains may be useful in evaluating the progression of neoplasms.  
 
 
 1 
CHAPTER 1 
INTRODUCTION 
 
 
1.1 DNA methylation in general 
Deoxyribonucleic acid (DNA) was identified in the mid 20th century as a cell’s genetic 
material. DNA is a polymer comprised of four nitrogenous bases: adenine (A), guanine (G), 
thymine (T) and cytosine (C). Unique combinations of these four bases encode the genetic 
information for all of the various life forms on earth. These unique combinations or “genomes” 
are faithfully passed to subsequent generations either by asexual or sexual reproduction, and thus 
patterns of inheritance emerge. The field of genetics has been dedicated to understanding DNA 
sequence and how sequence variation influences heritable differences in gene expression. 
However, geneticists have observed that not all patterns of inheritance can be explained by 
variations in genome sequences alone. In fact, there exist layers of heritable information in 
addition to genomic sequence variations that have profound influences on gene expression. Enter 
the field of epigenetics. In this section, a principle component of epigenetics, termed DNA 
methylation, is discussed in the context of the mammalian genome. It should be noted, however, 
that DNA methylation is a central epigenetic mechanism in other genomes including plants, 
fungi, insects, and even bacteria [1,2,3].  
DNA methylation is a layer of epigenetic information deposited directly onto nucleic acid 
content. Since it’s discovery, DNA methylation has been shown to be critical for regulating gene 
expression and cell fate decisions [4]. As such, improper regulation of DNA methylation has 
been linked to numerous human disorders and cancers [4,5]. In these cases, either excessive 
DNA methylation (i.e., hypermethylation) or deficient DNA methylation (i.e., hypomethylation) 
contributes to the onset of abnormal gene expression. However, these abnormal DNA 
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methylation settings often accompany each other as seen in human cancer. Therefore, many 
recent efforts have focused on not only understanding the contributions of DNA methylation to 
normal and abnormal cell function, but also how DNA methylation can either serve as an 
epigenetic biomarker or be targeted for therapeutic interventions [6]. These efforts are discussed 
in further detail below. 
The most common form of DNA methylation in mammals is 5-methylcytosine (5mC), which 
is the product resulting from the covalent addition of a methyl substituent to the 5th position of a 
cytosine ring (Figure 1.1) [4]. The methyl groups are deposited symmetrically onto both strands 
of the DNA double helix most often in cytosine-phosphate-guanine (CpG) palindromic 
sequences [4]. Occupancy of this position on cytosine residues at CpG sites spatially orients the 
methyl groups so that they protrude into the major grove of the DNA double helix (Figure 1.1) 
[7]. Thus far, there are two well-supported models that depict the function of this spatial 
orientation. First, the methyl groups cause steric hindrance, and thus block proteins from 
associating with DNA sequences containing methylated CpG sites [1]. Conversely, the methyl 
groups can serve as a docking site for certain proteins [1]. In either case, DNA methylation 
mostly functions to repress gene expression by blocking the binding of transcription factors to 
the DNA or by recruiting histone-modifying complexes that facilitate heterochromatin 
formation. However, in rare cases such as at the FoxA2 promoter, DNA methylation can also 
activate gene expression by inhibiting the association of transcriptional repressors with the DNA 
such as the Polycomb group proteins [8]. Nevertheless, DNA methylation acts to physically 
block proteins from interacting with DNA with the exception of proteins that have a methyl-
CpG-binding domain (MBD) such as methyl CpG binding protein 2 (MeCP2) [9,10].  
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Figure 1.1. DNA methylation on cytosine residues generates 5-methylcytosine. (A) Molecular 
structure of cytosine and 5-methylcytosine. DNA methyltransferase enzymes catalyze the 
covalent addition of methyl substituents onto cytosine residues to generate 5-methylcytosine. (B) 
Methyl substituents on 5-methylcytosine protrude into the major groove DNA double helix. Gold 
stars represent methyl substituents.  
 
 
In a broader view, DNA methylation is dispersed in varying degrees throughout major 
locations in the genome and has different regulatory implications depending on the underlying 
sequence on which it is deposited. DNA methylation is relevant to three major locations in the 
genome. First, CpG islands are regions of the genome that are enriched with CpG sites (i.e., 
genomic sequences at least 300bp long with greater that 50% GC content) and often co-localize 
with gene promoters [11]. CpG islands are typically void of DNA methylation with the exception 
of specific cases such as gene promoters that need to be silenced in certain cell types or when 
CpG islands are imprinted as differentially methylated regions (DMR) [4,11]. The absence of 
DNA methylation at CpG islands is permissive to gene expression [11]. However, the 
unmethylated profile of CpG islands can make them a target for local DNA hypermethylation 
events, and thus gene repression during carcinogenesis [12]. Second, intergenic regions are 
regions of the genome that are located between genes. Transposable elements, which make up 
conservatively 45% of the genome, are the main sequence elements found within intergenic 
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regions [13]. DNA methylation is abundant at mobile elements and is critical to inhibit their 
replication and subsequent insertion into new places of the genome, which can result in gene 
disruption and genomic instability [14]. Lastly, gene bodies are regions of the genome that 
contain the exons and introns of genes. However, the first exon is an exception as DNA 
methylation within this exon is also repressive to gene expression just as in promoter regions [4]. 
The function of DNA methylation within genes bodies is still unclear; however, it is 
hypothesized to be involved with regulating transcriptional splicing [15,16]. Also, there is 
competing evidence as to whether DNA methylation in gene bodies is associated with increased 
gene transcription depending on the mitotic state of cells [4]. In any case, DNA methylation is 
intricately tied to management of gene transcripts.  
DNA methyltransferase (Dnmt) enzymes are responsible for generating 5mC by catalyzing 
the transfer of a methyl substituent from S-adenyl methionine to cytosine residues (Figure 1.1) 
[17]. Dnmt enzymes are capable of adding the methyl group to completely unmethylated, native 
DNA (i.e., de novo DNA methylation) or to newly replicated, hemimethylated DNA (i.e., 
maintenance DNA methylation). The enzymes mainly responsible for de novo methylation are 
Dnmt3a and Dnmt3b, while Dnmt1 preferentially targets hemimethylated DNA to maintain 
DNA methylation patterns [18,19]. Dnmt3L is the fourth member of the Dnmt family of 
enzymes; however, Dnmt3L lacks the catalytic domain required for DNA methylation. Dnmt3L 
does, however, facilitate de novo DNA methylation by stimulating the catalytic activity of both 
Dnmt3a and Dnmt3b [20,21,22,23]. While Dnmt3a and Dnmt3b have been shown to be critical 
in targeting de novo methylation to sequence elements such as specific DMRs and transposable 
elements during development, Dnmt3L has been implicated in de novo methylation of a broader 
range of sequence elements due to its association with both Dnmt3a and Dnmt3b. While it is 
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understood that maintenance DNA methylation is stimulated by replication, it is less clear how 
cells target de novo methylation to specific regions of the genome. The current working 
hypotheses regarding factors that can influence de novo DNA methylation include: RNA 
interference (RNAi) mechanisms, recruitment by transcription factors, occupancy of DNA by 
transcription factors, and crosstalk with histone modifications [24,25,26,27,28,29]. Overall, the 
ability of cells to perform maintenance and de novo DNA methylation is critical for proper cell 
function and development; however, improper regulation of these pathways can have profound 
effects that can contribute to disease states.  
DNA methylation is not only written but also erased. There are two main models for DNA 
demethylation, passive and active demethylation. First, passive DNA demethylation does not 
require enzymatic activity. In this case, DNA methylation is diluted after successive rounds of 
cell division without activity of Dnmt1 and the accompanying maintenance DNA methylation of 
hemimethylated DNA produced during replication [30]. This pathway of demethylation is 
implicated in developing cells and quickly dividing tumor cells that either house a loss-of-
function mutation in the Dnmt1 gene or an epigenetic mutation that silences expression of the 
Dnmt1 gene [1]. Furthermore, passive demethylation has been exploited as a therapeutic option 
in cancer [31]. This therapeutic approach is further discussed below. Second, active DNA 
demethylation requires the enzymatic activity of either the ten eleven translocation (TET) family 
of proteins or the activation-induced cytidine deaminase/apo-lipoprotein B mRNA-editing 
enzyme complex (AID/APOBEC). In this case of the TET enzymatic pathway, DNA 
methylation is lost due to the direct modification of the methyl group on cytosine residues, which 
generates successive oxidized intermediates. The final oxidized form is then recognized by the 
base excision repair (BER) pathway, which replaces the oxidized form of 5mC with a naked 
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cytosine [32]. The activity of the TET enzymes and the resulting oxidized versions of 5mC are 
also implicated in cancer, which is further discussed below [33]. In the case of the 
AID/APOBEC pathway, the amino group is targeted for deamination. This effectively converts 
5mC to thymine, which is then improperly base paired with guanine. This T-G base pair 
mismatch also triggers the BER pathway [4]. Overall, the ability of cells to remove DNA 
methylation is critical for their normal function, but also has implications in disease states.  
DNA methylation is not a standalone epigenetic mechanism. In fact, DNA methylation acts 
in concert with other epigenetic mechanisms such as histone modification. In this case, DNA 
methylation can influence the histone code, and vice versa histone modifications can influence 
the activity of the Dnmt enzymes. First, as mentioned earlier, DNA methylation can serve as a 
docking site for MeCP2 [9,10]. Once bound to methylated DNA, MeCP2 can then recruit two 
classes of histone modifying complexes: histone methyltransferases that catalyze methylation of 
histone 3 lysine 9, and histone deacetylases that are responsible for removing acetyl moieties 
from lysine residues in histone tails [4]. Both of these changes to the local histone environment 
are repressive to gene expression, and thus are considered to reinforce the repressive nature of 
DNA methylation to gene expression. Second, histone modifications can directly influence the 
establishment of DNA methylation. In this case, certain histone marks can either facilitate or 
antagonize the establishment of DNA methylation. For example, while histone 3 lysine 27 
trimethylation can recruit the binding of Dnmt3a and stimulate its methytransferase activity, 
histone 3 lysine 4 trimethylation prevents DNA methylation by impairing the binding of all three 
Dnmt enzymes to histone 3 tails [34,35].  Overall, it is now clear that DNA methylation and 
histone modifications can not only influence the establishment of one another, but these layers of 
 7 
epigenetic information can support one another in regulating gene expression and ensuring 
inheritance of epigenetic information.  
 
1.2 DNA methylation in genomic imprinting 
Genomic imprinting is well known example of heritable differences in gene expression that 
is independent of genomic sequence variation. This concept was elegantly demonstrated in the 
early 1980s by experimentally transplanting murine pronuclear material to generate maternal and 
paternal uniparental embryos, none of which survived [36]. These assays allowed the researchers 
to conclude that the developing embryo requires both paternal and maternal contributions to its 
genome because each parental allele must express a different subset of genes. Subsequent 
experiments have identified specific genes that are expressed strictly from a single allele 
dependent upon whether the allele is paternally or maternally inherited [37,38,39,40,]. Further 
investigations lead to detecting differential DNA methylation between the paternal and maternal 
chromosomes, and that DNA methylation functions to repress transcription of imprinted genes 
from the allele on which it is deposited [12,36,41]. Thus, imprinted genes are referred to as either 
a paternally expressed gene or a maternally expressed gene. Thus far, at least 100 imprinted 
genes have been identified and mapped in the murine genome [36]. 
Imprinted genes tend to be clustered into distinct chromosomal domains that exhibit unique 
regulatory features including complex DNA methylation patterns, non-coding RNA, and 
enhancers [41]. First, imprinted domains contain cis-regulatory sequence elements termed DMRs 
that are differentially methylated in a parent-of-origin dependent manner. DNA methylation is 
deposited at DMRs either during gamete production or somatic cell differentiation, and thus a 
DMR is classified as either a gametic DMR or a somatic DMR, respectively [36,41]. The 
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fundamental difference between gametic and somatic DMRs is that the DNA methylation status 
at a gametic DMR can influence the expression of several imprinted genes in the domain, while 
DNA methylation at a somatic DMRs only influences expression of the imprinted gene that it is 
associated with. Therefore, gametic DMRs are designated imprinting control regions (ICRs) 
[36,41,42]. DNA methylation at DMRs functions as an epigenetic repressor within imprinted 
domains as imprinted gene promoters are often embedded within the DMR, and thus the 
respective imprinted gene is only expressed from the allele without DNA methylation. Second, 
imprinted domains feature long non-coding RNA (lncRNA) genes [41]. These lncRNA genes are 
also imprinted due to the DNA methylation settings within their respective domain and their 
promoter often being embedded within the domain’s ICR. Experimental truncation of Airn in the 
Igf2r domain and Kcnq1ot1 in the Kcnq1 domain revealed that these lncRNA genes function to 
regulate the mono-allelic expression of nearby protein coding genes whose promoters are not 
differentially methylated [43]. This demonstrates that DNA methylation can indirectly control 
the imprinting of genes in which it is not directly associated. Third, imprinted domains feature 
distal regulatory sequence elements termed enhancers. These sequence elements have been 
implicated to be involved with the spatial and temporal expression of imprinted as well as their 
proper mono-allelic expression [44,45]. As discussed in more detail below, DNA methylation at 
ICRs has a role in directing enhancers in the domains to associate with certain promoters [36,41]. 
The role of DNA methylation at the enhancer themselves however is still unclear; however, the 
transient nature of DNA methylation at enhancers may dictate when and in which tissues 
enhancers may associate with imprinted gene promoters in the domain [44]. Overall, imprinted 
domains are regulated by several epigenetic mechanisms acting in concert, with DNA 
methylation at ICRs being the central component that orchestrates the regulations.   
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As alluded to above, genomic imprinting is established by an intricate interplay among 
several epigenetic mechanisms. To date, three models of genomic imprinting have been 
proposed, all of which depend on parent-of-origin DNA methylation patterns at ICRs (Figure 
1.2) [46]. First, the insulator model is demonstrated at the H19/Igf2 locus [47]. In this case, DNA 
methylation deposited on the paternal allele at the H19 ICR inhibits the binding of the CCCTC 
binding factor (CTCF). Thus, CTCF is only allowed to bind the maternal allele. The docking of 
CTCF on the maternal allele prevents (insulates) downstream enhancers from interacting with 
the Igf2 promoter, and thus the enhancer element associates only with the H19 promoter on the 
maternal allele to stimulate expression. Due to the lack of interaction, DNA methylation is then 
deposited on the maternal allele at the Igf2 promoter/DMR ensuring transcriptional silencing. 
Oppositely, the DNA methylation imprint on the paternal allele spreads into the H19 promoter to 
ensure transcriptional silencing. The absence of CTCF occupancy on the paternal allele allows 
the downstream enhancers to associate with the Igf2 promoter to stimulate transcription.   
Second, the lncRNA model is demonstrated at the Igf2r locus [48]. In this case, DNA 
methylation at the ICR on the maternal allele silences transcription of the Airn lncRNA, which 
allows for Igf2r, Slc22a2 and Slc22a3 to be transcribed from the maternal allele. However, the 
lack of DNA methylation at the ICR on the paternal allele allows the Airn lncRNA to be 
transcribed. The Airn lncRNA then represses transcription of Slc22a2 and Slc22a3 by 
accumulating at the promoters of these genes on the paternal allele, which recruits the G9a 
protein to establish repressive histone marks [49]. The Airn promoter is antisense to Igf2r, and 
thus transcription of the Airn silences Igf2r expression from the paternal allele.  
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Figure 1.2. Models of genomic imprinting. Empty lollipops represent unmethylated CpG islands. 
Filled in lollipops represent methylated CpG islands. Black bars represent genes. Pink arrows 
represent maternally expressed genes. Blue arrows represent paternally expressed genes. Red 
strikethrough signs represent silenced gene expression. Purple bars represent enhancer elements.  
T-bars represent inhibition. (A) Insulator model. (B) Long non coding RNA model. (C) Enhancer 
competition model.  
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Third, the enhancer competition model is demonstrated at the Peg3 locus [50]. In this case, 
the DNA methylation status at the ICR determines whether an upstream enhancer will interact 
with the bidirectional promoter for Peg3 and Usp29 or with Zim1 promoter. When the ICR is 
unmethylated on the paternal allele, the bidirectional Peg3 and Usp29 promoter outcompetes the 
Zim1 promoter to associate with the upstream enhancer. However, DNA methylation at the ICR 
on the maternal allele inhibits the bidirectional Peg3 and Usp29 promoter from interacting with 
the enhancer, and thus the enhancer is now free to interact with the Zim1 promoter. Overall, 
DNA methylation at ICRs is central to controlling the parent-of-origin expression of several 
genes within an imprinted domain.   
DNA methylation at ICRs must be erased and rewritten to ensure the proper parent-of-origin 
expression profiles in offspring. This epigenetic reprogramming happens during gametogenesis 
in the parents; however, there are slight differences between spermatogenesis and oogenesis. 
First, the epigenetic reprogramming occurs at different developmental stages of male and female 
gametogenesis. While imprints are erased in both male and female primordial germ cell lineages, 
the male germ line undergoes prenatal de novo DNA methylation at ICRs whereas the female 
germ line undergoes postnatal de novo DNA methylation at ICRs during oocyte maturation [41]. 
The functional role for this difference in activity of de novo DNA methylation in each germ line 
is still unclear. Second, different sets of genes are imprinted in the two germ lines. Although it is 
not fully understood how each germ line targets each set of genes for imprinting, recent reports 
have shed some light on this mystery in the developing oocyte. This series of experiments 
discovered a link between transcription originating from upstream alternative promoters to ICRs 
and activity of de novo DNA methylation at ICRs in the oocyte [51,52]. However, it is still 
unknown whether developing spermatocytes employ this same mechanism to target de novo 
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DNA methylation at ICRs as paternally methylated ICRs tend to be within intergenic regions. 
Nevertheless, developing spermatocytes and oocytes have to globally reset DNA methylation 
and subsequently rewrite DNA methylation at specific imprinted loci to establish paternal and 
maternal imprints, respectively. Overall, this epigenetic cycling implies mechanisms are in place 
within imprinted domains that can recruit both de novo DNA methylation machinery as well as 
DNA demethylation machinery to ICRs.  
 
1.3 DNA methylation in cancer 
The onset of cancer has classically been attributed to genomic mutations that critically 
change gene functions. Irreversible sequence changes that impact gene function undoubtedly 
drive carcinogenesis [4]. However, it is now well accepted that improper regulation of epigenetic 
information can coordinate with genomic mutations to increase tumor heterogeneity to promote 
clonal expansion [53]. As a stable and strong epigenetic repressive signal, DNA methylation has 
gained considerable attention as a major factor that contributes to critical changes in gene 
expression to promote carcinogenesis. Indeed, DNA methylation in tumor cells is improperly 
regulated as both hypermethylation and hypomethylation is observed in a single primary tumor 
[54]. While DNA hypomethylation patterns are more widespread throughout the genome, DNA 
hypermethylation tends to be more focal in nature occurring at regions that are functionally 
relevant to promote a given tumor type [12,55]. Thus, different patterns of hypo-and 
hypermethylation are selected for and fixed in different populations of tumor cells. Unique 
patterns of methylation have also been correlated with different stages of progression of a single 
primary tumor [54]. Somatic evolution of tumor cells drives this selection process, which 
effectively generates unique heritable molecular signatures among the various forms and stages 
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of cancer. These molecular signatures combined with the ease at which DNA methylation 
changes can be detected, make DNA methylation an ideal candidate as a biomarker to enhance 
cancer prognosis. Furthermore, the plasticity of DNA methylation makes it a prime target for 
therapeutic interventions. 
DNA hypermethylation mainly functions to suppress gene expression in tumor cells [12,55]. 
As mentioned above, DNA hypermethylation in tumor cells occurs in a rather focal manner. It is 
not yet understood how focal DNA hypermethylation patterns arise. First, certain regulatory 
sequence elements may be specifically targeted for DNA hypermethylation. Conversely, DNA 
hypermethylation may occur in a random fashion and only certain hypermethylation events that 
confer a competitive advantage for a given tumor cell over adjacent normal cells are selected for 
and fixed by clonal expansion. Nonetheless, focal DNA hypermethylation has been reported 
most often at CpG islands containing promoters of tumor suppressor genes; however, frequent 
hypermethylation of enhancer elements has recently been reported [56]. In either case, DNA 
hypermethylation can negatively impact gene dosage. Overall, DNA hypermethylation during 
carcinogenesis has been reported to inactivate genes involved in the following cellular processes: 
cell-cycle, apoptosis, angiogenesis, DNA damage repair, cell differentiation, transcription, and 
signal transduction [4,12,55]. 
 DNA hypomethylation may contribute to carcinogenesis in a variety of ways.  While DNA 
hypermethylation is clearly demonstrated to be locus-specific, DNA hypomethylation tends to 
occur throughout the genome mostly at repeated sequences, which can have several implications. 
For example, transposable elements are frequently hypomethylated during carcinogenesis [4,57]. 
Transposable elements are a main class of repeat sequences that have the unique ability to move 
around the genome by either cut and paste or a copy and paste mechanisms [58]. DNA 
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methylation at transposable elements inhibits their ability to move around in the genome, and 
thus losing DNA methylation at these repeat elements can release their ability to transpose. 
When a transposable element inserts into a new location it can disrupt gene activity. Thus, 
hypomethylation at transposable elements can increase mutation rates in a tumor cell, which in 
turn can increase the rate at which of the tumor cell progresses toward malignancy [59]. 
Centromeric regions are another example of repetitive sequences that are frequently 
hypomethylated. In this case, loss of DNA methylation decreases centromere stability leading to 
increased chromosomal rearrangement within centromeric regions [4,57]. In either case, genomic 
instability is increased with DNA hypomethylation, which in turn leads to higher mutation rates 
and acceleration through carcinogenesis.  
ICRs contain sequence elements that make them attractive targets to aberrant DNA 
methylation during carcinogenesis [60]. First, ICRs contain at least one CpG island, which 
makes them targets for DNA hypermethylation. Second, ICRs contain tandem repeat sequences, 
which makes them targets for DNA hypomethylation. In either case, aberrant DNA methylation 
at ICRs can potentially impact the proper regulation of imprinting within the domain. For 
example, DNA hypermethylation at the ICR within the H19/Igf2 domain in colorectal cancer 
correlated with loss of imprinting for Igf2 by allowing the upstream enhancer to associate with 
the Igf2 promoter on both alleles [61]. This report demonstrated that ICRs are primed for the 
Knudson two hit hypothesis, which posits that the accumulation of mutations are required for the 
onset of cancer [62]. For imprinted genes, genomic imprinting on one allele provides the first 
“hit” and subsequent aberrant DNA hypermethylation on the other allele can serve as the second 
“hit” to relieve genomic imprinting within the domain. Oppositely, DNA hypomethylation of the 
imprinted allele can also relieve genomic imprinting and for example result in bi-allelic 
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expression of imprinted genes with oncogenic potential. Overall, only one allele within imprinted 
domains needs to be targeted for either hyper-or hypomethylation to fulfill the Knudson two hit 
hypothesis and promote carcinogenesis.  
 
1.4 Statement of research objectives 
DNA methylation has been extensively studied in the last few decades. These studies have 
demonstrated that DNA methylation is a central epigenetic mechanism regulating gene 
expression especially in the context of genomic imprinting, which in its own merit is a complex 
heritable gene dosage mechanism. Abnormal DNA methylation is an epigenetic mutation 
frequently detected in a variety of mammalian tumors. In this study, the epigenetic stability of 
imprinted domains is hypothesized to be particularly susceptible during carcinogenesis because 
DNA methylation changes at ICRs need to occur at only one allele to effectively relieve genomic 
imprinting within the domain, potentially resulting in the simultaneous increased expression of 
imprinted genes with oncogenic potential and decreased expression of imprinted genes with 
tumor suppressor activity. Thus, the Knudson “two hit” hypothesis is satisfied with only a single 
epigenetic “hit” to an ICR. The hypothesis of this study is further supported by the notion that 
progression through carcinogenesis is a Darwinian selection process of cells that gain a 
reproductive advantage over their normal cell counterparts by accumulating both genetic and 
epigenetic mutations that promote cell division.  
Abnormal DNA methylation within imprinted domains is not a stranger to cancer. However, 
the epigenetic stability of imprinted domains throughout carcinogenesis is not fully understood. 
First, it is largely unknown when DNA methylation settings go awry within imprinted domains 
during carcinogenesis. Second, it is unclear which regulatory sequence elements within 
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imprinted domains experience significant DNA methylation changes: are epigenetic changes in 
imprinted domains equally distributed or are certain regulatory sequence elements targeted? This 
study sought to address these questions by characterizing the epigenetic response of imprinted 
domains by profiling DNA methylation changes during carcinogenesis driven by an oncogenic 
mutation. A better understanding of when DNA methylation settings are altered within imprinted 
domains during carcinogenesis will increase our understanding of how improper regulation of 
imprinted genes contributes to carcinogenesis. Furthermore, the results from this study may be 
adapted to clinical settings as epigenetic biomarkers during prognosis. 
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CHAPTER 2 
EPIGENETIC INSTABILITY AT IMPRINTING CONTROL REGIONS 
IN A KRASG12D-INDUCED T-CELL NEOPLASM1 
 
2.1 Introduction 
DNA methylation at ICRs ensures proper dosage of imprinted genes by restricting their 
expression from only one allele based upon parental origin [1].  This strict gene dosage control 
makes sense given the fact that imprinted genes have critical roles in controlling fetal growth 
rates, brain functions and energy regulations [1,2].  The biochemical functions of many 
imprinted gene products are also in accordance with these roles, as they tend to be clustered in 
signaling pathways responsible for either cell growth or death [3,4,5].  Consequently, 
perturbations to the epigenetic modifications that regulate imprinted gene dosage have been 
implicated as factors contributing to neoplastic transformation of tumor cells [6,7].  Among the 
approximate 100 imprinted genes identified thus far, the following genes are frequently 
associated with cancer: Igf2 (Insulin-Like Growth Factor 2), Igf2r (Igf2 Receptor), Gnas 
(stimulatory GTPase alpha), Dlk1 (Delta-Like 1 Homolog), Peg10 (Paternally Expressed Gene 
10), Peg3 (Paternally Expressed Gene 3), Plagl1/Zac1 (Pleiomorphic Adenoma Gene-Like 1), 
Grb10 (Growth Factor Receptor-Bound Protein 10), Ube3A (Ubiquitin Protein Ligase E3A) and 
Mest (Mesoderm-Specific Transcript) [8].   
Imprinting Control Regions are the key cis-regulatory elements that dictate the allele-specific 
expression patterns for entire imprinted domains [1].  ICRs and their associated allele-specific 
DNA methylation patterns are critical for establishing and maintaining genomic imprinting [9].  
When an ICR is hyper-or hypomethylated it cannot properly control expression of the multiple 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  This	  chapter	  first	  appeared	  as: Bretz CL, Langohr IM, Lee S, Kim J. (2015) Epigenetic 
instability at imprinting control regions in a Kras(G12D)-induced T-cell neoplasm. Epigenetics 
10(12): 1111-20. doi: 10.1080/15592294.2015.1110672. 
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mRNAs in the domain by either activating ncRNA in cis or interacting with proteins that insulate 
promoters from distal enhancer elements [10].  Given the role DNA methylation plays in the 
proper function of ICRs, it is reasonable to predict that aberrant DNA methylation of ICRs could 
disrupt the imprinting of entire domains, which could then contribute to malignant 
transformation.  Indeed, both DNA methylation and genomic imprinting are challenged in cancer 
[11,12].  Therefore, within imprinted domains, ICRs may be particularly vulnerable to aberrant 
DNA methylation during tumor progression.  However, the timing and prevalence of DNA 
methylation changes at ICRs have not been systematically investigated in the context of 
carcinogenesis.   
To test if ICRs are particularly susceptible to epigenetic insult during carcinogenesis, we first 
induced lymphoblastic T-cell thymic lymphoma in mice using the KrasG12D mutation under 
control of the Cre/LoxP system, and then systematically characterized DNA methylation changes 
within imprinted domains during the progression of the disease from an early stage 
(hyperplastic) to a late stage (neoplastic).  According to the results, DNA methylation changes 
tend to be restricted to certain regulatory elements within imprinted domains and accumulate 
progressively among the imprinted domains as the disease advances toward more infiltrative 
states.  NGS-based bisulfite sequencing also revealed that certain CpG sites tend to avoid DNA 
methylation changes within ICRs that show overall change.  In sum, this study demonstrates that 
DNA methylation changes are frequent and dynamic at ICRs during lymphoblastic T-cell thymic 
lymphoma carcinogenesis.  
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2.2 Results 
Oncogenic KrasG12D expression results in an infiltrative T-cell neoplasm. In this study, we 
challenged a subset of murine cells in vivo with the KrasG12D mutation and concomitant 
abrogation of PEG3 protein seeking to test Peg3 as a tumor suppressor.  To accomplish this, we 
employed two floxed alleles: LSL-KrasG12D and Peg3floxed (Figure 2.1). First, the LSL-KrasG12D 
allele features a floxed set of polyA termination signals inserted between the 1st and 2nd exons of 
the Kras locus. The 2nd exon is modified with a point mutation causing a substitution (glycine to 
aspartic acid) for the 12th amino acid of the KRAS protein [13,14]. The termination cassette 
prevents transcription of the oncogenic KrasG12D form until it is removed by the activity of cyclic 
recombinase (Cre) (Figure 2.1). Second, the Peg3floxed allele features the 6th exon flanked by two 
loxP sites and thus is excised upon Cre-mediated recombination [15,16]. The PEG3 protein 
cannot be translated from the modified ORF of Peg3del6 due to a frame shift and subsequent 
nonsense mutation. Therefore, when the recombined allele (Peg3del6) is paternally transmitted, 
the result is the abrogation of PEG3 protein due to the introduced mutation on the paternal allele 
and the silencing of the maternal allele by genomic imprinting (Figure 2.1).    
To target these mutations to various tissues/cell types in mice, we employed an allele, 
MMTV-Cre, which drives expression of Cre by the Mouse Mammary Tumor Virus (MMTV) 
long terminal repeat promoter (Figure 2.1) [17]. This allele has been shown to express Cre in 
many of the same cell types where Kras and Peg3 are both expressed [18]. The employed 
breeding scheme yielded four cohorts (Figure 2.1). The two experimental cohorts were LSL-
KrasG12D; Peg3floxed; MMTV-Cre (KPM) and LSL-KrasG12D; MMTV-Cre (KM), whereas the two 
negative control cohorts were Peg3floxed; MMTV-Cre (PM) and MMTV-Cre (M).  In cells 
expressing MMTV-Cre, the proteins produced for each cohort are as follows: KPM (KRASG12D 
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and Cre), KM (KRASG12D, PEG3 and Cre), PM (Cre), and M (PEG3 and Cre).  Specific PCR 
genotyping of thymic DNA confirmed expected recombinant products for each cohort (Figure 
2.1). 
   
Figure 2.1. Targeting oncogenic KrasG12D expression and PEG3 deletion to the mouse thymus. 
(A) Upon Cre-mediated recombination: the allele housing the KrasG12D mutation (denoted by 
*12D) is conditionally expressed by removal of a tandem polyA signal.  The critical exon six 
(denoted by yellow coloration) of Peg3 is conditionally deleted. Blue font denotes the allele is 
paternally inherited and pink font denotes the allele is maternally inherited. Grey boxed denote 
exons. Black triangles denote loxP sites. Filled in lollipops denote a methylated CpG island. 
Empty lollipops denote an unmethylated CpG island. (B) Breeding schematic from mating LSL-
Kras+/G12D; Peg3+/del6 mice with MMTV-Cre mice to generate KPM, KM, PM, and M cohorts. 
(C) Specific PCR analysis of genomic DNA isolated from thymus confirms recombinant 
products for each of the targeted alleles. 
 
We obtained 17 litters from the breeding scheme described above, which yielded a total of 91 
mice consisting of 12 KPM, 26 KM, 10 PM, and 43 M (Figure 2.2). In general, there were no 
obvious differences in the gross physical appearance of individuals for each cohort at birth; 
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however, by one month of age, the coat for both KPM and KM mice appeared glossy and thin. 
This phenotype is thought to be the result of sebaceous gland hyperplasia (Figure 2.3). After one 
month of age, both KPM and KM mice started developing squamous papillomas on their mucus  
 
Figure 2.2.  Gross features of mice expressing the KrasG12D mutation. (A) Kaplan-Meier 
comparative survival analysis of KM, KPM, PM and M cohorts. Median survival of KPM and 
KM mice was significantly less than PM and M cohorts (p < 0.001, log-rank test, for each 
pairwise combination). (B) Organ weight profiles of KPM, KM, PM and M cohorts. Spleen and 
liver percent of body weight was significantly increased in KPM and KM cohorts (p < 0.001, 
pairwise T-test). (C) Images of hepatomegaly, enlarged thymus, and splenomegaly. 
 
membranes, both oral and perianal (Figure 2.3). This is consistent with observations from 
previous studies of LSL-KrasG12D mice [19]. The squamous papillomas caused discomfort for the 
animals such that they experienced difficulties eating and defecating to a point that the animals 
of the KPM and KM cohorts often experienced significant weight loss (15% of body weight) by 
two-to-four months of age. Furthermore, within this time period, we observed that mice in both 
the KPM and KM cohorts started to experience labored breathing, lethargy, and signs of pain. 
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Based on these observations, it was deemed necessary to euthanize animals showing signs of 
distress or significant weight loss. As a result, the survival of experimental cohorts (KPM and 
KM) was significantly reduced (p < 0.001) compared to that of the negative control cohorts (PM  
 
Figure 2.3. Histological features of mice expressing the KrasG12D mutation. (A-F) 
Representative histopathology of skin, liver and spleen (magnifications in parentheses), H&E 
staining. (A) Facial skin of a MMTV-Cre (M) control mouse (100X) shows the normal thickness 
of the epithelial layer and the normal number of sebaceous glands/hair follicles (arrows). (B)  
Perianal skin of an L-KrasG12D;MMTV-Cre (KM) experimental mouse (40X) shows a squamous 
papilloma characterized by multiple finger-like projections of thickened epithelium accompanied 
by sebaceous gland hyperplasia as evident by multiple glands associated with each hair follicle 
(arrows).  (C) Liver of an M control mouse (40X) with the normal lobular architecture (P = 
portal region; M = midzonal region; C = centrilobular region). (D) Liver of a KM experimental 
mouse (40X) with marked extramedullary hematopoiesis corresponding to the basophilic cell 
infiltrate evident primarily in the portal and centrilobular areas. (E) Spleen of an M control 
mouse (100X) with the normal architecture, characterized by white (W) and red (R) pulp. (F) 
Spleen of a KM experimental mouse (40X) with marked extramedullary hematopoiesis 
expanding the red pulp (R) and lymphohistiocytic proliferation obscuring the white pulp (W).    
 
and M) such that the median survival for both experimental cohorts was approximately 90 days 
(Figure 2.2). However, there was no significant difference in survival between the two 
experimental cohorts, KPM and KM (p = 0.8).  These data indicate that the Peg3del6 allele in 
KPM mice did not have any additional effect on survival.  Both negative control cohorts did not 
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show any signs of distress, and remained healthy throughout the duration of the experiment.  
Furthermore, both experimental cohorts, KPM and KM, experienced significant burden due to 
increased size of liver (8.0±1.1%, p < 0.001 and 11.3±1.8, p < 0.001, mean percent of body 
weight respectively), spleen (3.0±1.5%, p < 0.001 and 5.1±1.5 %, p < 0.001, mean percent of 
body weight respectively) and thymus compared to those of negative control littermates (Figure 
2.2). Thymus data were not collected due to the size reduction of this organ as the negative 
control mice age. In KPM and KM mice, the pressure imposed by the over-sized liver and spleen 
most likely resulted in abdominal pain, and the pressure imposed by the over-sized thymus most 
likely caused partial lung collapse resulting in shortness of breath and lethargy. Furthermore, 
histopathological analyses of the liver and spleen revealed that these two organs had marked 
extramedullary hematopoiesis accompanied, in the spleen, by lymphohistiocytic proliferation in 
the white pulp (Figure 2.3). In summary, expression of KrasG12D was primarily responsible for 
the observed phenotypes and expression of Peg3del6 did not enhance or contribute to these 
phenotypes.  
The mice expressing KrasG12D developed an infiltrative thymic neoplasm. One-month-old 
mice had marked expansion of the cortex by a heterogeneous cell population composed of small 
and large lymphocytes (Figure 2.4). Older, three-month-old, mice had the thymic architecture 
completely effaced by dense sheets of neoplastic lymphoid cells morphologically consistent with 
lymphoblast (Figure 2.4) [19,20,21,22]. Furthermore, neoplastic cells were CD3 positive and 
PAX5 negative (Figure 2.4). Neoplastic cells variably infiltrated the adjacent adipose tissue, the 
dorsal root ganglia, the myocardium at the base of the heart, the wall of the ventral (sternum) and 
dorsal thorax, and the ventral neck musculature (Figure 2.4). 
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The percent of mice developing lymphoblastic T-cell thymic lymphoma was similar for both 
experimental cohorts, KPM and KM, each at 40%. This could be explained by the fact that anti-
PEG3 staining in control and experimental mice was negative suggesting that PEG3 is not 
produced in any cell type within the thymus (Figure 2.5). Because previous studies have  
 
Figure 2.4. Histological thymic alterations in KM mice. (A) The cortex is expanded by a 
heterogeneous (hyperplastic) lymphoid cell population, with retention of the normal thymic 
architecture in a 1-month-old KM mouse. (B) The architecture of the hyperplastic thymus in a 1-
month-old KM mouse is maintained, with the majority of CD3 immunopositive cells in the 
cortex. (C) The normal architecture of the thymus is completely effaced by a lymphoid round 
cell neoplasm in a 2.5-month-old KM mouse.  (D) Neoplastic lymphoid cells effacing the thymus 
in a 2.5-month-old KM mouse are diffusely CD3 immunopositive, consistent with T-cell origin 
of the neoplasm. (E-G) H&E staining of nearby tissues. (E) Neoplastic cells invade adjacent 
adipose tissue. (F) Neoplastic cells encircling ganglia. (H) Neoplastic cells invade the 
myocardium at the base of the heart (G) Neoplastic cells invade the musculature of the sternum. 
All insets show to neoplastic cells at 400X.  
 
suggested that Yin-yang 1 (YY1) may be a suppressor of Peg3 expression, we also performed 
anti-YY1 staining; however, similar to the anti-PEG3 staining, YY1 was not detected in any cell 
population within the thymus (Figure 2.5). Thus, these data indicate that the KrasG12D mutation is 
sufficient to initiate the development of an infiltrative T-cell neoplasm within the mouse thymus, 
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and that the Peg3del6 mutation does not enhance the latency of KrasG12D-induced T-cell 
lymphoma.   
 
Figure 2.5. Neither PEG3 nor YY1 protein is produced in the thymus. (A-F) Representative 
immunohistochemistry from anti-PEG3 and anti-YY1 staining of positive control tissue (testis), 
hyperplastic tissue (thymus) and neoplastic tissue (thymus).  (A&B) Immunostaining of testis 
confirms the efficacy of the PEG3 and YY1 antibodies, respectively.  (C&D) Immunostaining of 
thymus containing a hyperplastic cell population from a L-KrasG12D;MMTV-Cre (KM) mouse 
can not detect PEG3 or YY1 proteins, respectively. (E&F) Immunostaining of thymus containing 
neoplastic cell population from a KM mouse can not detect PEG3 or YY1 proteins, respectively. 
 
DNA methylation changes at ICRs during progression of KrasG12D-induced lymphoblastic T-
cell thymic lymphoma. For DNA methylation analyses, 15 experimental samples of the thymus 
(12 from KM mice and 3 from KPM mice) were selected: five hyperplastic, five atypically 
hyperplastic and five neoplastic lesions as determined from clinical and pathological 
observations.  The DNA methylation profiles of the experimental tissue samples were compared 
to those of negative control samples from the M cohort. Combined Bisulfite Restriction Analysis 
was used to initially screen for DNA methylation differences (COBRA, [23]).  This series of 
analyses derived the following observations. First, significant changes in DNA methylation were 
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more frequently observed within ICRs than the promoters of Tumor Suppressor Genes (TSG). 
For example, five ICRs (Ig, Peg10, Peg3, Nespas, and Grb10) were significantly 
hypermethylated, whereas only two TSG promoters (Mgmt and Fhit) were significantly 
hypermethylated, in the most advanced tumor sample (Figure 2.6). The most affected was the Ig-
ICR, showing significant hyper-methylation in 73% of the samples. In contrast, 
hypermethylation within promoters of the most affected TSGs, Mgmt and Fhit, was only 
detected in 20% of the samples. Collectively, 60% of DNA from lymphoblastic T-cell thymic 
lymphoma displayed aberrant DNA methylation in two or more ICRs, whereas only 6% of these 
DNA displayed aberrant DNA methylation in two or more TSG promoters (Figure 2.6). 
 
Figure 2.6. Signature of aberrant DNA methylation in KrasG12D-induced lymphoblastic thymic T-
cell lymphoma. Heat map summary of the quantified COBRA data for all ICRs tested in 15 
thymic samples. Based on p values from pairwise T-test, each locus tested in the thymic samples 
was determined to be hypermethylated (red), hypomethylated (green), or not changed (grey).  
The gradation of yellow in the sample # column depicts progression of the disease state from 
hyperplastic (white) to atypically hyperplastic to neoplastic (yellow).  
 
Second, the majority of changes observed in ICRs were hypermethylation.  Only the Peg10-
ICR displayed either hyper- or hypo-methylation among 60% of the samples. In this case, the 
frequency of hypermethylation was 0.13, whereas the frequency of hypomethylation was 0.47. 
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Interestingly, hypomethylation of the Peg10-ICR was the only detectable change in three out of 
the five hyperplastic samples (Figure 2.6). Thus, these data indicate that aberrant DNA 
methylation in the Peg10-ICRs may be one of the first detectable changes in lymphoblastic T-
cell thymic lymphoma. 
Third, several tumor samples displayed both hyper- and hypo-methylation in the tested ICRs 
(Figure 2.7). In sample 6, the mean percent methylation of the Peg10-ICR reduced to 29±4%     
 
  
Figure 2.7.  DNA methylation profiles of DMRs in thymic lymphoma. Mean percent methylation 
generated by COBRA of imprinting control regions and differentially methylated regions within 
imprinted domains that displayed significant changes among 16 thymus samples: 1 normal 
sample (N) and 15 experimental samples expressing KrasG12D (1-15).   
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(p = 0.006), yet mean percent methylation drastically increased to 84±2% (p < 0.001) in the Ig-
ICR and 87±6% (p < 0.001) in the Peg3-ICR (Figure 2.7 and Figure 2.8). These coexisting 
hyper- and hypo-methylation data indicate that changes within ICRs are not the result of global 
changes to the methylome towards hypermethylation at CpG islands; rather, these changes are 
the result of discrete events. In summary, these data demonstrate that aberrant DNA methylation 
within ICRs is precocious and dynamic in T-cell lymphoma. The complete set of mean percent 
methylation graphs for each ICR and DMR with significant changes is available (Figure 2.7 and 
Figure 2.8).      
DNA methylation changes at distal enhancers within imprinted domains during progression 
of KrasG12D-induced lymphoblastic T-cell thymic lymphoma. We also surveyed DNA 
methylation in other regulatory regions within imprinted domains. First, we measured DNA 
methylation changes at distal enhancers since these elements are known to be vulnerable during 
carcinogenesis [24]. For this test, we measured the DNA methylation levels of a putative 
enhancer found within the Peg3 domain, termed ECR18 (Figure 2.8) [25]. According to the 
results, the Peg3-ICR displayed significant hypermethylation in 6 out of 15 samples (#2, 4, 6, 8, 
10, and 14), and Peg3-ECR18 displayed significant hypermethylation in 7 out of 15 samples (#2, 
6, 7, 8, 9, 12 and 14). Interestingly, sample #7 displayed similar methylation levels at both the 
Peg3-ICR (62±9%) and Peg-ECR18 (55±12%). However, the change in methylation was only 
significant for Peg3-ECR18 due to the low level of methylation at the enhancer region and 50% 
methylation at the ICR in normal tissue. Furthermore, the Peg3-ECR18 displayed significant 
hypermethylation in samples #9 and #12 while the ICR remained unaffected suggesting that the 
enhancer region acquired DNA methylation changes before the ICR. 
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Figure 2.8.  Distal enhancer regions may prove to be effective biomarkers. (A-B) Aberrant DNA 
methylation comparison of the Peg3-ICR and the Peg3-ECR18. (A) COBRA of the Peg3-ICR. 
(B) COBRA of the Peg3-ECR18. Unmethylated DNA is denoted with a U. Methylated DNA is 
denoted with a M. Stars represent significant increases in DNA methylation compared to normal 
DNA (denoted by the letter N).  Experimental samples are numbered 1-15.  Red represents 
hypermethylation, grey represents no change, and blue represents normal/control levels.   
 
Second, we also surveyed the DNA methylation levels of the differentially methylated region 
(DMR) and promoter for the two imprinted genes, Gnas and Dlk1 (Figure 2.9). Interestingly, 
neither the DMR nor the promoter for either gene displayed any changes in DNA methylation.  
However, the ICRs for both genes frequently experienced significant changes.  The ICR for the 
Gnas domain, Nespas-ICR, was hypermethylated in 3 out of 15 samples and the ICR for the 
Dlk1/Gtl2 domain, Ig-ICR, was hypermethylated in 11 out of 15 samples (Figure 2.9). These 
data demonstrate that ICRs are more sensitive to DNA methylation changes than DMRs or 
promoters.  Taken together, these results demonstrate that ICRs and enhancer elements are both 
more sensitive to DNA methylation changes than DMRs or promoters, and that changes in 
methylation within enhancer elements may be more readily detectable.   
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Figure 2.9.  Aberrant DNA methylation is targeted to ICRs within imprinted domains. Images 
generated from COBRA analysis of three regulatory regions within the Gnas and Dlk1/Gtl2 
domains.  For each domain, the ICR, a nearby DMR and a nearby promoter were measured. 
Unmethylated DNA is denoted with a U, while methylated DNA is denoted with an M. The 
enzymes used to digest each amplicon are presented under the name of each PCR product.  
 
Bisulfite sequencing revealed hypermethylation-resistant CpG sites within ICRs. We also 
performed NGS-based bisulfite sequencing for a subset of the PCR products to get a more 
holistic view of DNA methylation changes. PCR products were selected from seven 
experimental samples (4 KM and 3 KPM) and one control sample (N).  Results from the Peg3-
ICR are displayed as a representative set (Figure 2.10). Inspection of the sequencing results 
allowed for the following observations. First, sequencing results were mostly consistent with the 
results generated by COBRA, confirming that there was a correlation between DNA methylation 
levels and the degree of tumor progression in the tested samples (Figure 2.6 and Figure 2.10). In 
the hyperplastic sample (#13), the DNA methylation pattern was consistent with the pattern in 
the control sample (N), where approximately one half of the heat map was red (denoting 
methylated CpG sites) and the other half was blue (denoting unmethylated CpG sites). This is the  
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Figure 2.10. Bisulfite NGS reveals not all CpG are equally vulnerable to DNA methylation 
changes. Heat maps generated by BiQ analyzer HT showing DNA methylation at each CpG 
(Nos. 1-16) within bisulfite PCR products. Results from the Peg3-ICR are shown as a 
representative set. Each column represents a CpG within the bisulfite PCR product and each row 
represents a sequencing read. The positions of the restriction sites utilized in COBRA are 
indicated below the heat map of the control sample (N) with triangles (black for TaqαI and purple 
for HphI). Mean methylation (%) and number of reads are presented above each map. Below the 
heat maps is a UCSC genome browser view of putative CSEl containing CpGs Nos. 4-7. 
Sequences are highlighted based on matching the consensus motif of the SP1 transcription factor.  
An expansion of CSE1 is proposed based on the most hypermethylation resistant CpG, #3, being 
contained in a highly conserved region that matched very well with the SP1 binding motif and 
was not included in putative CSE1.    
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typical pattern generated by normal levels of DNA methylation due to ICRs being methylated on 
one allele and unmethylated on the other. However, the normal pattern was no longer present in 
neoplastic samples such as #2, representing the most advanced tumor. This sample was 
hypermethylated to such an extent that mean methylation was nearly 84%, which rendered the 
portion of the heat map representing the unmethylated allele virtually non existent (Figure 2.10). 
Second, certain CpG sites were resistant to DNA methylation change. Within the amplicon 
for the Peg3-ICR, this trend was evident by a subset of CpG sites maintaining the normal half red 
and half blue pattern even though other CpG sites were methylated in 90% or more of 
sequencing reads. The CpG sites particularly maintaining the normal pattern were Nos. 3,4,7,12 
and 13 (Figure 2.10). Inspection of the sequences surrounding these resistant CpGs indicated that 
these sites are part of potential regulatory sequences.  CpG Nos. 3,4 and 7 are part of the GC-box 
motif, 5’- GGGCGG -3’, and CpG Nos. 12 and 13 are part of the palindrome, 5’- CGATCG -3”.  
Two of the CpGs Nos. 4 and 7 are within a putative conserved sequence element (CSE1) that is 
known to attract an unknown repressive protein complex to the Peg3-ICR [26,27]. Interestingly, 
another conserved GC-box motif happens to be localized just outside CSE1, yet this is the motif 
housing the most resistant CpG site No. 3 based on its methylation status most evident in the heat 
map for sample #2 (Figure 2.10). Overall, this series of analyses demonstrated that DNA 
methylation changes expand during tumor progression and that certain CpG sites might be 
protected from DNA methylation changes potentially due to the binding of unknown 
transcription factors.  
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2.3 Discussion 
Analyses of many human cancers suggest that the methylation status of genomic imprinting 
is challenged during carcinogenesis and that loss of imprinting (LOI) contributes to neoplastic 
transformations [12]. However, the context (i.e., the causative genomic mutation) in which DNA 
methylation changes occur within imprinted domains can rarely be determined. Furthermore, it 
may not be possible to determine which mutation, the genomic or the epigenomic, is established 
first in sporadic human tumors.  Further complicating matters, DNA methylation signatures 
within imprinted domains vary from one tumor type to the next [8]. Therefore, it is necessary to 
survey DNA methylation of imprinted domains in various tumor types in which the causative 
genomic mutation is known. Here, we induced lymphoblastic T-cell thymic lymphoma in mice 
using the KrasG12D oncogene and systematically surveyed for aberrant DNA methylation within 
imprinted domains. With this study, we show that DNA methylation in imprinted domains is 
frequently challenged in T-cells expressing KrasG12D (Figure 2.6) and that DNA methylation 
changes do not occur equally within an imprinted domain. Rather, these changes occur most 
frequently at ICRs (or “control DMRs”) and enhancers (Figure 2.7 and Figure 2.9) of imprinted 
domains. Furthermore, we found that certain evolutionarily conserved sequence elements that 
attract DNA binding proteins are resistant to DNA methylation changes (Figure 2.10). Overall, 
the ICRs of the Peg10, Dlk1/Gtl2 and Peg3 domains experienced the most notable DNA 
methylation changes in T-cell lymphoma (Figure 2.6).  
Aberrant DNA methylation within the Peg10 and Dlk1/Gtl2 domains has also been reported 
in human B-cell leukemias and malignancies [8]. The consistency of these two domains 
experiencing changes in both B-cell and T-cell neoplasms has several implications. First, 
detecting DNA methylation changes cannot be used to determine the cell type responsible for 
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lymphocytic tumors. However, detection of aberrant DNA methylation within imprinted domains 
may provide insight into the severity of a disease.  For instance, while the only detectable 
changes in hyperplastic tumors occurred in the Peg10 and Dlk1/Gtl2 domains, changes were 
frequently detected within several other domains such as Peg3 in neoplastic tumors (Figure 2.6). 
Thus, detection of aberrant DNA methylation in imprinted domains other than Peg10 and 
Dlk1/Gtl2 suggests lymphocytes have already undergone neoplastic transformation. Second, 
because the Peg10 and Dlk1/Gtl2 domains experience detectable changes in hyperplastic tumors, 
changes in these domains may contribute to neoplastic transformation. If this does prove to be 
the case, then specific therapeutic modalities may be designed to restore normal DNA 
methylation settings within these domains. Lastly, neither the causative genomic mutation nor 
the specific cell type may be directly responsible for changes in DNA methylation. Rather, 
distinct DNA methylation signatures are likely established based on whether or not the 
epimutation provides a selective advantage for a given tumor cell.  
 ICRs contain a variety of DNA sequence elements that have been linked to hyper- and 
hypomethylation trends, which are notorious for increasing cancer heterogeneity [28, 29]. These 
sequence elements include tandem repeats, CpG islands, and ncRNA promoters, all of which 
often co-exist within an ICR [1]. For instance, while CpG islands tend to attract 
hypermethylation, tandem repeat sequences frequently become hypomethylated [28]. Thus, any 
given ICR has the potential to either gain or lose methylation. This phenomenon is showcased 
quite nicely by our analysis of the Peg10-ICR.  The Peg10-ICR was hypomethylated in seven 
samples and hypermethylated in two samples among the nine T-cell neoplasms that displayed 
DNA methylation changes within this region. PEG10 has been derived from retrotransposons, 
which may account for the frequent hypomethylation. At the same time, the ICR of the Peg10 
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domain contains a CpG island, which may account for the hypermethylation. Therefore, the 
unusual clustering of various sequence elements within ICRs may be what first attracts DNA 
methylation changes. Most often, the changes that occur at ICRs will not contribute to disease 
progression. However, when certain epimutations at ICRs do contribute to the carcinogenesis of 
a particular tumor cell type, they can be selected for and propagated by rapidly dividing tumor 
cells until the epimutation is fixed in what now can be considered an evolved population of 
tumor cells. 
DNA methylation changes are primarily restricted to ICRs within an imprinted domain. 
Invasive breast cancer frequently displays aberrant DNA methylation within several imprinted 
domains and loss of imprinting does not necessarily accompany DNA methylation changes [30]. 
However, it is still unclear whether the observed methylation changes could be the result of 
shifting DNA methylation boundaries or specific DNA methylation changes contained within 
imprinted domains [30]. According to the results of our analyses of the Dlk1/Gtl2 and Gnas 
domains, the ICRs of these domains frequently experienced aberrant DNA methylation, but 
regions outside of the ICRs (i.e., nearby DMRs and promoter regions) were not affected (Figure 
2.7). Therefore, we believe that DNA methylation changes are not the result of shifting DNA 
methylation pattern. Rather, aberrant DNA methylation is confined to certain regions of 
imprinted domains, particularly ICRs.  
ICRs are unusually sensitive to DNA methylation changes during carcinogenesis, but there 
may be other regions of the genome that are just as sensitive. While surveying the Peg3 domain, 
we observed that an evolutionarily conserved region (ECR18), a putative enhancer for the Peg3 
domain, was hypermethylated at a similar frequency even though it is 200 kb upstream from the 
Peg3-ICR (Figure 2.9). Although this observation implies that enhancer regions may also be 
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unusually sensitive to DNA methylation changes during carcinogenesis, further investigations 
into several other enhancer regions are needed to confirm this preliminary observation. However, 
this observation is consistent with recent reports that demonstrated DNA methylation of 
transcriptional enhancers is associated with cancer predisposition [31]. It will certainly be 
interesting to further investigate how changes in DNA methylation at enhancer regions can 
impact nearby gene expression profiles within tumor cells and how such changes contribute to 
carcinogenesis. If enhancer regions do prove to be particularly vulnerable to DNA methylation 
changes in tumor cells, they could make excellent biomarkers given their ubiquitous distribution 
in the genome.   
Bisulfite sequencing analyses revealed that DNA methylation changes are not only variable 
among ICRs, but also variable within a single ICR. For instance, while the sequencing results 
were consistent with the COBRA results, they also revealed an unexpected pattern in tumor cells. 
Certain CpG sites remained unaffected even though neighboring CpG sites experienced 
extensive hypermethylation.  Upon close inspection of the immediate sequences surrounding the 
resistant CpG sites, we noticed that these sites are within the GC-box motif, 5’- GGGCGG -3’ 
(Figure 2.10). There are two possibilities that may be responsible for this trend. First, certain 
CpG sites remain unaffected due to the binding of unknown transcription factors, which may 
have a role in genomic imprinting or transcription of imprinted genes within the region. Second, 
the unaffected CpGs may simply be within DNA segments that are less accessible to the DNA 
methyltransferase machinery due to nucleosome occupancy. Since the only observed resistant 
sites were part of well-known consensus sequences, we favor the first scenario that these CpG 
are shielded from DNA methylation because of being bound by proteins. However, we plan to 
further investigate this hypothesis in the near future.  
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Previously, we have identified a conserved sequence element (CSE1) within the Peg3 
domain.  According to the results, an unknown protein complex binds to CSE1, and this complex 
is predicted to be a strong repressor for the expression of Peg3 [26,27]. Upon close inspection of 
the CpG sites (Nos. 4-7) of the Peg3-ICR amplicon, which are localized within putative CSE1, 
we realized CpGs sites Nos. 4 and 7 are part of a well-known motif, the GC-box. Oddly, there 
was a CpG site (No. 3) immediately outside the 42-bp-putative CSE1 sequence that is also part 
of a GC-box motif. Interestingly, this CpG site was most resistant to DNA methylation and is 
highly conserved among placental mammals (Figure 2.10). Furthermore, when we included the 
slightly degenerate sequences surrounding the core sequence of the GC box, we noticed a 
surprising trend: these evolutionarily conserved sequences fit very well with the consensus 
sequence, 5'-(G/T)GGGCGG(G/A)(G/A)(C/T)-3', known to be bound by the SP1 transcription 
factor [32] (Figure 2.10). The CpG sites within this consensus sequence resisting DNA 
methylation change is consistent with a previous study which reported that the SP1 protein 
protects CpG islands from de novo DNA methylation [33]. Although this observation suggests 
SP1 as a possible candidate protein binding to this region, further testing is required to support 
the hypothesis that SP1 binds to CSE1 and subsequently regulates Peg3 expression. Nonetheless, 
the current results suggest that the previously defined region of CSE1 may need expansion to 
include the outlying GC-box as a conserved cis-regulatory module (Figure 2.10). 
To our knowledge, this is the first study to challenge murine cells with a potent oncogenic 
mutation and then systematically survey imprinted domains for aberrant DNA methylation. The 
results from the DNA methylation analyses of this study demonstrate that the DNA methylation 
status of ICRs is unstable and that aberrant DNA methylation accumulates among several ICRs 
during carcinogenesis of lymphoblastic T-cell thymic lymphoma. Whether the observed DNA 
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methylation changes within ICRs directly contribute to the development of a tumor cell 
population or are merely the result of the accumulation of changes over time in the tumor cell 
methylome is still unknown and requires further investigation. However, considering that the 
function of many imprinted gene products is frequently associated with physiological cellular 
processes such cell growth and death and how sensitive imprinted genes dosage is to these 
physiological processes, it is likely that changes within ICRs for a subset of imprinted genes such 
as Peg10, Dlk1, Gnas, and Peg3 could alter gene expression and tip the scales such that a tumor 
cell population could gain a competitive edge and proliferate with fewer checks and boundaries.    
 
2.4 Materials and Methods 
Three mouse stains were maintained for the duration of the experiment.  Two publically 
available mouse strains, B6.129-Krastm4Tyj/Nci (LSL-KrasG12D) and STOCK Tg(MMTV-
Cre)4Mam/J (MMTV-Cre), were purchased from Jackson Laboratories [13,14,15].  The third 
strain, Peg3floxed, was generated in the lab [16,17].  The order of breeding was carried out as 
follows: first, the Peg3floxed allele was bred with the LSL-KrasG12D model to generate double 
heterozygous mice. Next, male double heterozygous mice for Peg3floxed and LSL-KrasG12D were 
bred with female homozygous MMTV-Cre mice.  This breeding scheme yielded progeny with 
four different genotypes: KPM, KM, PM, and M.  All experiments were performed in 
accordance with National Institutes of Health guidelines for care and use of animals, and also 
approved by the Louisiana State University Institutional Animal Care and Use Committee 
(IACUC), protocol #13-061. 
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All litters were weaned 21 days post partum and littermates were separated by gender based 
on comparing the relative distance of the genitalia from the perianal membrane.  No more than 
five littermates were housed in a single cage.  Littermates were identified through varying 
positions of a hole punch on the left ear.  Genomic DNA from a right ear clip was used for PCR 
genotyping. Ear clips were lysed overnight at 60ºC in a solution with tail lysis buffer (Tris-HCl 
pH 8.1 100 mM, EDTA 5 mM, NaCl 200 mM, SDS 0.2%) supplemented with Proteinase K 
(NEB, Cat. No. P8107S).  Lysates were diluted at 1:60 with nanopure water.  Two microliter of 
diluted lysate was directly added to Maxime PCR Premix tubes (intron, Cat. No. 25167) 
followed by 1 µl of primer at the concentration of 10 pM and nanopure water to bring the 
reaction to 20 µl. The following specific primer sets were used for each of the following mouse 
strains: Peg3FlpKo/Del6: Peg3 5arm 5’-CCCTCAGCAGAGCTGTTTCCTGCC-3’ and Peg3 LoxR 
5’-TGAACTGATGGC GAGCTCAGACC-3’ and Peg3 rev 5’-
ACCCCATTCTCATCAGCTCCAGAG-3’; MMTV-Cre: MMTV-Cre F 5’-CTGATCT 
GAGCTCTGAGTG-3’ and MMTV-Cre R 5’-CATCACTCGTTGCATCGACC-3’; LSL-
KrasG12D: Kras F1 5’-GTCTTTCCCCAGCACAGTGC-3’ and Kras Fcass 5’-
AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3’; L-KrasG12D: Kras F1 5’-
GTCTTTCCCCAGCACAGTGC-3’ and Kras R1 5’-CTCTTGCCTACGCCAC CAGCTC-3’. 
Genotyping PCR conditions for 33 cycles were as follows: denaturation at 95ºC for 30 seconds, 
annealing at 60ºC for 30 seconds, and extension at 72ºC for 1 minute.  
Mice were sacrificed by CO2 asphyxiation in accordance with the rules and regulations set 
forth by the IACUC either when showing signs of distress or when reaching 15% weight loss 
(weight measurements were taken every three days for mice expressing the KrasG12D mutation).  
A full necropsy was performed on all mice.  Tissues were fixed in 10% neutral buffered formalin 
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(Thermo Scientific, Cat. No. 5725) for at least 48 hours, and then transferred to 70% ethanol for 
storage.  Tissues were trimmed and embedded in paraffin, sectioned, and stained with 
hematoxylin and eosin (H&E).  Sections were evaluated by a board-certified veterinary 
pathologist (IML).  Samples of oral, anal and foot pad masses and any other tissue that appeared 
grossly abnormal were also placed in lysis buffer containing Proteinase K for subsequent DNA 
extraction and analyses.  The standard method was used for immunohistochemistry.  Briefly, 
paraffin blocks were sectioned at 5 µm and deparaffinized (three xylene changes, 5 min each; 
three washes with 100% ethanol, 4 min each; one wash with 95% EtOH, 4 min; one dH2O rinse; 
and one buffer rinse).  Slides were soaked in 3% H2O2/dH2O for 10 min to quench endogenous 
peroxidase activity, and were incubated with normal goat blocking serum for 30 min.  Antigen-
retrieval was performed with a Biocare Decloaker for 20 min in DAKO citrate buffer pH 6.  
Primary antibodies were diluted with the DAKO antibody diluent, and were applied at room 
temperature for 30 minutes for anti-CD3 (Santa Cruz Biotechnology, Cat. No. sc-1127), anti-
PAX5 (Santa Cruz Biotechnology, Cat. No. sc-1974) and anti-Peg3 [17], and one hour for anti-
YY1 (Santa Cruz Biotechnology, Cat. No. sc-7341).  The following primary antibody dilutions 
were used: anti-CD3 (1:350), anti-PAX5 (1:300), anti-Peg3 (1:50), and anti-YY1 (1:100).  
Biotinylated anti-goat in rabbit and biotinylated anti-rabbit in goat secondary antibodies were 
diluted with the DAKO antibody diluent and applied to the slides.  Slides were counterstained 
with Hematoxylin. Staining was performed on a DAKO Autostainer Link 48.   
Genomic DNA was purified from mediastinal tissue samples by spin column recovery 
(Genomic DNA clean and concentrator-25, Zymo Research, Cat. No. D4065).  Purified genomic 
DNA (500 ng) from each mediastinal lesion was bisulfite-converted using a commercial kit (EZ 
DNA methylation kit, Zymo Research, Cat. No. D5002).  The converted DNA was used for PCR 
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amplification.  The detailed information regarding the sequences and genomic position for each 
oligonucleotide set has been presented as (table 2.1).  The amplified PCR products from 
bisulfite-converted DNA were digested with restriction enzymes, separated on a 2% agarose gel, 
and the relative amount of each digested DNA fragment was measured based on its band density 
as described below.  QuantityOne software was used to export gel electrophoresis images as 
lossless tiff files (Gel Doc system, BioRad).  Tiff files were then processed as 8-bit grayscale 
using ImageJ software [34] in the following manner: 1) data was inverted; 2) background was 
subtracted using default setting; 3) brightness/contrast was adjusted by selecting the auto adjust 
command one time; 4) bands in each lane were selected individually using the rectangular tool; 
5) density plots were then generated for each rectangular selection; 6) each density peak was 
gated at the base of the peak at a location higher then background signals using the line drawing 
tool; and 7) the area under each peak was automatically generated by the software using the 
wand tool.  Area results were exported into an Excel spreadsheet where all subsequent analyses 
were performed.  DNA Methylation values (%) were calculated using the following formula: 
100*((area of peak from digested DNA/s)/(area of peak from digested band/s + area of peak 
from undigested DNA)).  ANOVA (single factor) statistical analysis was performed on the 
percent methylation results for each locus screened.  If the p value from the ANOVA analysis 
was less than or equal to 0.05, then subsequent pair wise T-test (two sample assuming equal 
variance) was performed comparing each tumor sample to normal tissue for each locus.  Three 
independent trials starting from bisulfite conversion to restriction digestion were repeated to 
derive the average DNA methylation levels of each locus within 95% confidence intervals.  
Sequencing of the individual bisulfite PCR products was performed using a NGS platform 
(PGM2, Ion Torrent, Life Technologies).  Briefly, bisulfite PCR products for each locus from 
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each trial were pooled for seven representative thymic lesions, and for one control thymus.  End 
repair was performed using a commercially available module (NEBNext End Repair Module, 
Cat. No. E6050S).   End-repaired bisulfite PCR products were then visualized by electrophoresis, 
size-selected, and extracted using a commercially available kit (Gel DNA recovery kit, Zymo 
Research, Cat. No. D4001).  Barcoded adapters were ligated to each thymic lesion’s pooled 
bisulfite PCR products by the activity of two enzymes in concert (Bst 2.0 WarmStart, NEB, Cat. 
No. M0538S and T4 DNA ligase, NEB, M0202S).  The adapter ligation reactions were 
visualized with gel electrophoresis, and the products were extracted using the Zymo kit 
referenced above. PCR with primers specific for the adapters was used to enrich for the PCR 
products that had the proper adapter orientation.  The enriched PCR products were then 
submitted to the genomics core facility at Louisiana State University (LSU) for sequencing.  The 
raw sequence reads were processed in the following manner.  Briefly, Sequence reads smaller 
than 100 bp in length were discarded.  The remaining sequences were first sorted by bar code for 
each thymic lesion, and then sorted by the primer sequences specific for each PCR product such 
that forward and reverse reads were sorted into the same directory.  The BiQ Analyzer HT tool 
was used to further process the sorted sequences such that reads with greater than or equal to 
80% bisulfite conversion and 50% sequence identity were analyzed to calculate DNA 
methylation levels for each locus [35].  The bioinformatics pipeline used for this process is 
available upon request.   
For each animal, date of birth and date of necropsy were recorded and compared by Kaplan 
Meyer survival analyses of the four cohorts using GraphPad Prism Version 4.0 software.  
However, for ease of formatting, Microsoft Excel was used to generate the survival curve graph.  
Upon necropsy, each animal’s body, liver, spleen and right kidney weights were measured using 
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a thermo scientific digital scale with 0.001g accuracy.  Data was imported into Microsoft Excel 
and was processed in the following manner.  Each organ’s percent of body weight was calculated 
mean % weight = 100*(weight of organ/total body weight).  For each cohort, mean percent 
weight of kidney, spleen and liver was calculated and plotted with 95% confidence intervals. 
ANOVA (single factor) was used to compare the percent weights of each organ type among the 
four cohorts. If the p-value from the ANOVA analysis was less than or equal to 0.05, then 
subsequent pairwise T-tests (two sample assuming equal variance) were performed to compare 
each cohort to one another for each organ type.  
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CHAPTER 3 
ABERRANT DNA METHYLATION AT IMPRINTING CONTROL REGIONS 
CORRELATES WITH AN INFILTRATIVE GROWTH PATTERN 
 
3.1 Introduction  
Imprinted genes are mainly expressed from a single allele based upon the allele’s parental 
origin [1]. Thus far, there have been just over 100 imprinted genes identified by conventional 
methodology; however, a far greater number of imprinted genes may exist due to recent data 
obtained by implementing modern whole-transcriptome sequencing technologies [2,3]. 
Nevertheless, the well-known imprinted genes are clustered in discrete chromosomal domains, 
which often contain a differentially methylated master cis-regulatory element termed an 
Imprinting Control Region (ICR) [1,4,5]. ICRs are accompanied by other cis-regulatory elements 
such as enhancers and differentially methylated promoters that act synergistically within their 
respective imprinted domain to elegantly control imprinted gene dosage [1,6]. While DNA 
methylation is transient among the other cis-regulatory elements depending on developmental 
contexts and cell types, DNA methylation at ICRs is exceedingly stable [1,6,7]. The stability of 
this epigenetic mark at ICRs is paramount due to their control over several imprinted genes 
within a domain that have key roles in cell growth, division or death [8,9,10]. Consistent with 
this, imprinted genes have gained much attention as both tumor suppressor genes and oncogenes 
[11,12,13,14,15]. Indeed, epigenetic perturbations within imprinted domains have been reported 
in a variety of both human and mouse malignant neoplasms [16,17]. However, the timing in 
which epigenetic change occurs within imprinted domains, especially at ICRs, is still unclear.  
DNA methylation is an important epigenetic regulator of gene expression. Misregulation of 
DNA methylation in tumor cells is well recognized as an epigenetic alteration that results in 
significant expression level differences of genes that contribute to the carcinogenic process 
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[14,15,18,19,20,21]. The genome of any given normal cell by default is virtually stifled with 
DNA methylation, with the exception of specific gene promoters and cis-regulatory elements 
such as enhancers that contribute to the expression of genes necessary for the proper function of 
the respective cell. However, during carcinogenesis, the levels of DNA methylation are 
drastically reduced genome wide [22]. There are two distinct drastic reductions in 5-
methylcytosine that occur throughout the genome during the carcinogenic stages: first, during the 
transition of normal cells to immortalized tumor cells, and second, as benign tumor cells acquire 
infiltrative capacity [22]. Interestingly, hypermethylation at specific regulatory elements such as 
tumor suppressor gene promoters occurs concomitantly with genome wide hypomethylation 
during these critical transitional stages. Although ICRs have been well identified as targets for 
hypermethylation, the functional role that this epigenetic aberration plays during the 
carcinogenesis process remains largely uncharacterized [16,17]. Does hypermethylation at ICRs 
contribute to the initiation of tumor formation, the proliferation of tumor cells, or the transition 
of a benign process to that of an infiltrative one?  
In the current study, we exploited the KrasG12D genomic mutation to initiate carcinogenesis 
in mice and surveyed the epigenetic stability at ICRs in two fundamentally different neoplasms: 
squamous papilloma that remains a benign process but exhibits continual growth, and T-cell 
lymphoblastic lymphoma that rapidly acquires infiltrative capacity. This comparison allowed 
further characterization of the functional role that aberrant DNA methylation at ICRs plays 
during the carcinogenic process. According to the results, ICRs remain epigenetically stable 
during the initiation of carcinogenesis and throughout the growth of tumors. However, DNA 
hypermethylation was observed across virtually all ICRs in infiltrative tumor cell populations 
regardless of their duration. These data suggest ICRs are targeted during the second phase of 
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DNA methylation alterations to the genome and epigenetic instability among ICRs contributes to 
the infiltrative capacity of tumor cells. Detailed results and the relevant discussion are presented 
below. 
 
3.2 Results 
In this study, we sought to test whether the instability of DNA methylation at ICRs is 
primarily associated with the transition of tumor cells to more infiltrative states. We also sought 
to compare the relative stability of DNA methylation at ICRs with that of other regulatory 
sequences such as Evolutionarily Conserved Regions (ECRs) that are known to be putative 
enhancers and associated with the ICR of their respective imprinted domain. To accomplish this, 
we utilized a floxed allele that contains the oncogenic KrasG12D mutation to initiate 
tumorigenesis. The LSL-KrasG12D allele contains a Lox-Stop-Lox (LSL) transcriptional stop 
cassette within the first intron, and a point mutation in the second exon that causes a substitution 
(glycine to aspartic acid) at the 12th amino acid of the KRAS protein (Figure 3.1) [23,24]. Upon 
the activity of cyclic recombinase (Cre), the stop cassette is removed from the 1st intron allowing 
transcription to proceed and produce a full-length transcript that encodes the oncogenic 
KRASG12D protein.   
It has been previously reported that the KrasG12D mutation is sufficient to initiate both an 
infiltrative T-cell neoplasm and benign squamous cell papilloma [16,25,26]. Here, we bred mice 
that express Cre under the Mouse Mammary Tumor Virus long terminal repeat promoter 
(MMTV-Cre) with the LSL-KrasG12D line to simultaneously target oncogenic KrasG12D to T-
cells and epithelial cells (Figure 3.1) [27,28]. Using this breeding scheme, we obtained 80 mice 
from 11 litters with an average litter size of about 7. Of the 80 total mice, 28 were positive for  
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Figure 3.1. Targeting oncogenic KrasG12D to mouse T-cells and epithelial cells. (A) Structure 
of the conditional LSL-KrasG12D allele. Once Cre removes the transcriptional stop cassette, 
transcription of oncogenic KrasG12D proceeds. (B) Breeding scheme involving mouse lines 
LSL-KrasG12D and MMTV-Cre. The numbers in parentheses indicate how many pups were born 
in each litter, the red number indicates the average litter size, and the blue numbers indicate how 
many mutant mice were obtained out of the expected number based on Mendelian inheritance. 
(C) Gross image of a thymic T-cell lymphoma that is markedly expanding the anterior 
mediastinum in a KrasG12D mouse. (D) Gross image of a squamous papilloma in and around the 
mouth of a KrasG12D mouse. (E) Histological image of a thymic T-cell lymphoma in a 
KrasG12D mouse with neoplastic lymphoid cells completely effacing the normal architecture of 
the thymus and surrounding mediastinal soft tissue (200x magnification). (F) Histological image 
of a squamous papilloma in a KrasG12D mouse showing the proliferated epithelium forming 
multiple finger-like projections with maintenance of the tissue boundaries (100x magnification). 
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the recombined KrasG12D allele, which deviated significantly from the expected Mendelian 
ratio (P=0.007, chi-square). All of the recombinant progeny developed squamous papilloma      
and nearly 40% developed thymic lymphoma as well as squamous papilloma (Figure 3.1) [16]. 
Unlike the thymic lymphoma, which infiltrated and extensively replaced the surrounding tissues 
(Figure 3.1), the squamous papillomas were benign. The squamous papilloma lesions retained an 
exophytic growth pattern with an overall thickening of the epithelial layer into fingerlike 
projections (Figure 3.1). In sum, a mouse breeding scheme utilizing KrasG12D/MMTV-Cre mice 
was successful in obtaining mice that developed both benign and infiltrative lesions.  
DNA methylation at ICRs remained stable with the 50% methylation levels in benign tumor 
cells, but became unstable with hypermethylation showing greater than 50% methylation levels 
in infiltrative tumor cells (Figure 3.2). We sampled 15 squamous papilloma tumors and 
measured the DNA methylation levels by COmbined Bisulfite Restriction Analysis COBRA at 
11 ICRs, including Igf2r, Zac1, H19, Grb10, Ig, Nespas, Peg10, Peg3, Mest, Snrpn, and Rasgrf1 
[16, 29, 30, 31]. The 15 tumors varied in age from 1 month to 4 months and thus size from small 
to large. Nevertheless, DNA methylation at ICRs remained stable throughout the growth of all 
the squamous papilloma tumors. This was apparent, as the ratio of digested bisulfite PCR 
amplicons (representing methylated DNA) to undigested amplicons (representing unmethylated 
DNA) in the tumors samples was not significantly different from the ratio of normal tissue 
samples. We then compared these methylation data in squamous papilloma to that of thymic 
lymphoid proliferative lesions histologically determined to be hyperplastic, atypical hyperplastic, 
and neoplastic [16,32,33]. While DNA methylation at ICRs remained stable in hyperplastic and 
atypical hyperplastic cells, it became unstable in infiltrative neoplastic cells (Figure 3.2). DNA 
methylation significantly changed at 9 of the 11 ICRs tested, including H19, Grb10, Ig, Nespas,  
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Figure 3.2. DNA methylation signatures at ICRs in benign squamous papilloma and infiltrative 
thymic T-Cell lymphoma. (A) Representative DNA methylation data from 11 ICRs in squamous 
papilloma and thymic lymphoid proliferative lesions generated by COBRA. Data from 7 out of 
the 15 squamous papilloma tumors are shown and compared to a sample of normal skin denoted 
with an N. Data from 1 normal thymus (N) and 3 representative thymic lymphoma samples are 
shown: A – hyperplastic, B – atypical hyperplastic, and C – neoplastic. The red C denotes where 
hypermethylation at ICRs occurred. Unmethylated DNA is denoted with a blue U, and 
methylated DNA is denoted with a red M. (B) Summary of DNA methylation changes at the 11 
ICRs in papilloma and thymoma. Red coloration represents significant hypermethylation based 
on at least 2 of 15 samples having a P value less than 0.05.  
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Peg10, Peg3, Mest, Snrpn, and Rasgrf1 (Figure 3.2). In sum, the stability of DNA methylation at 
ICRs displayed a major difference between tumor cells of different states, benign versus 
infiltrative.  
Certain regulatory sequence elements within imprinted domains became epigenetically 
unstable in the nonmalignant setting. We surveyed the DNA methylation status of various 
regulatory sequence elements (ICRs, somatic differentially methylated regions (DMRs), ECRs, 
and promoters) within three imprinted domains (Peg3, Grb10, and H19) to compare the 
epigenetic stability of the ICRs to other sequence elements within their respective imprinted 
domains (Figure 3.3). We found that there was no clear trend as to which type of sequence 
element first experiences epigenetic change; rather, certain sequence elements experienced 
significant changes in DNA methylation in the benign squamous papilloma lesions. Specifically, 
the Zfp264 promoter of the Peg3 domain became significantly hypermethylated in 5 out of 15 
tumors (Figure 3.4); whereas, the ICR and ECR18 of the Peg3 domain showed no significant 
change in DNA methylation (Figure 3.3). On the contrary, the ECR1 of the H19/Igf2 domain 
became significantly hypermethylated in 2 out of 15 tumors (Figure 3.4); whereas, none of the 
other sequence elements in the domain showed significant change in DNA methylation (Figure 
3.3). While certain sequence elements in both the Peg3 and H19/Igf2 domains experienced 
significant changes in DNA methylation, all sequence elements in the Grb10 domain remains 
stable in all squamous papilloma lesions (Figure 3.3). In sum, the DNA methylation at all four 
elements tested, ICRs, DMRs, promoters and ECRs, behave similarly during carcinogenesis, 
although some elements are affected earlier than others in individual cases.  
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Figure 3.3. DNA methylation signatures of various sequence elements within imprinted domains 
in squamous papilloma and thymoma. (A) Peg3 domain structure. Sequence elements analyzed 
include Zim2 – Differentially Methylated Region (DMR), Zim1 promoter, APeg3 promoter, Peg3 
– Imprinting Control Region (ICR), ECR18, and Zim3/Zfp264 – DMR. (B) Grb10 domain 
structure. Sequence elements analyzed include Ddc – promoter, ECR154, Grb10 – ICR, Grb10 
promoter, and Cob1 promoter. (C) H19/Igf2 domain structure. Sequence elements analyzed 
include ECR2, H19 promoter, H19 – ICR, ECR1, and Igf2 – DMR. All sequence elements are 
listed in order as they appear in the figure from left to right.  
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Figure 3.4. Representative COBRA data from the H19 – ECR1 and the Zfp264 – promoter. 
Squamous papilloma samples are numbered 1-15 and compared to a sample of normal skin (N). 
The numbers underneath the gel images indicate percent methylation for each sample. Red 
numbers indicate the samples that showed significant DNA methylation change based on P 
values less than 0.05. Unmethylated DNA is denoted with a blue U and methylated DNA is 
denoted by a red M.  
 
 
3.3 Discussion 
Many efforts have been focused on determining the potential role that imprinted genes may 
play during carcinogenesis [11,12,16,17,22,34,35,36]. Analyses of human malignant neoplasms 
have revealed that many ICRs and putative enhancers within imprinted domains show significant 
epigenetic change pertaining to DNA methylation, and that these changes often correlate with the 
expression level differences of nearby imprinted genes within the domain [17]. However, the 
question whether this epigenetic instability within imprinted domains contributes to the 
infiltration potential of tumor cells remains elusive [16]. In the current study, we initiated 
tumorigenesis in mice with the KrasG12D mutation, and subsequently compared the epigenetic 
stability of various regulatory sequence elements within imprinted domains between two 
fundamentally different neoplasms, benign squamous papilloma and malignant T-cell 
lymphoma. We show that there is a stark contrast in the epigenetic stability at ICRs between the 
benign and infiltrative lesions studied: while DNA methylation among ICRs was stable in the 
benign lesions, including in the thymic lymphoid hyperplastic lesions, it was highly unstable in 
the infiltrative lesions. Furthermore, we show that DNA methylation is unstable at certain 
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regulatory sequence elements specific to their imprinted domain in both the benign and 
malignant lesions. Overall, it appears that imprinted domains are most vulnerable to epigenetic 
change in infiltrative tumor cells.   
DNA methylation settings at ICRs are critical for maintaining parent-of-origin specific 
expression of many genes within an imprinted domain [7]. ICRs contain various sequence 
elements that commonly manifest aberrant DNA methylation trends in tumor cells [19]; thus, the 
stability of DNA methylation at ICRs is concerning in the context of carcinogenesis. Moreover, 
ICRs are susceptible to the Knudson two-hit hypothesis because one allele is already methylated 
and silenced in the native state. Therefore, ICRs can potentially respond to either 
hypomethylation events or hypermethylation events. Indeed, the Knudson two-hit hypothesis has 
been well supported with hypermethylation of imprinted genes in malignant tumors [14,16,17]. 
However, the timing when ICRs manifest epigenetic change, particularly DNA methylation 
changes, is debatable. First, do epigenetic changes at ICRs coincide with the initiation of 
carcinogenesis or, second, do epigenetic changes at ICRs coincide with neoplastic transformation 
of tumor cells? 
According to the results of our analyses of the squamous papillomas, DNA methylation at 
ICRs remained stable throughout the duration of these benign tumors (Figure 3.2). This suggests 
that, epigenetic instability at ICRs is not associated with the early events of carcinogenesis. 
However, this epigenetic stability is particularly intriguing given that two genome-wide DNA 
demethylation events take place in mouse skin carcinogenesis: first, during transition from 
immortalized non-tumorigenic keratinocytes to benign papilloma cells and, second, during 
transition from epithelial to spindle cells, which is associated with a sharp increase in infiltrative 
potential (Figure 3.5) [22]. Moreover, these genome-wide reductions in 5-methylcytosine are  
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Figure 3.5. DNA methylation trends during carcinogenesis. (A) Depicts the genome wide 
reductions in 5-methylcytosine during the transition of normal cells to benign tumor cells (first 
hash mark) and when benign cells gain infiltrative potential (second hash mark). (B) Depicts 
specific hypermethylation events that coincide with the genome wide hypomethylation trends. 
Red line represents hypermethylation at Tumor Suppressor Gene (TSG) promoters and the blue 
line represents hypermethylation at Imprinting Control Regions (ICRs).  
 
 
accompanied by two waves of DNA hypermethylation at specific tumor suppressor gene 
promoters [22]. Unfortunately, we were unable to analyze the epigenetic activity at ICRs during 
the second wave of DNA methylation changes in the squamous papilloma panel as these 
epithelial cells did not undergo the epithelial-mesenchymal transition. Furthermore, these 
squamous tumors did not even advance to squamous cell carcinomas. Nevertheless, the 
epigenetic stability at ICRs throughout the first reconstruction of the epigenome suggests 
imprinted genes do not have a role in the initiation of carcinogenesis.  
Epigenetic stability at ICRs is challenged during the second reconstruction of the DNA 
methylome (Figure 3.5). This wave of DNA methylation changes is associated with increase in 
the infiltrative potential of tumor cells. This is demonstrated by the results from the T-cell 
lymphoblastic lymphoma panel (Figure 3.2). In addition to neoplastic thymic lymphoid lesions, 
this panel also included hyperplastic and preneoplastic thymic lymphoid lesions [16]. ICRs 
remained epigenetically stable in the hyperplastic and preneoplastic specimens regardless of the 
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duration of the lesions. In contrast, malignant neoplastic specimens displayed marked epigenetic 
instability with nearly all the ICRs becoming hypermethylated, regardless of the duration of the 
lesion. ICRs acquiring hypermethylation does not necessarily confer repression of imprinted 
genes as seen with hypermethylation in tumor suppressor gene promoters [35]. For instance, 
hypermethylation at the ICR of the H19/Igf2 domain can potentially result in complete 
repression of H19 and bi-allelic expression of Igf2, a known oncogene, whereas 
hypermethylation at the ICR of the Peg3 domain can potentially result in repression of Peg3, a 
putative tumor suppressor [5]. Thus, concomitant hits to multiple ICRs can simultaneously 
activate oncogenes while suppressing tumor suppressor genes. Overall, it appears ICRs are 
targeted to be hypermethylated in the midst of the second drastic genome wide reduction in 5-
methylcytosine, a hallmark of tumor progression to malignant disease. This raises the notion that 
epigenetic instability among ICRs could enhance the infiltrative capacity of tumor cells.   
The epigenetic stability among the ICRs in the benign tumors is not a common theme among 
other regulatory sequences within their respective imprinted domain. This is demonstrated by our 
analysis of the H19/Igf2 and Peg3 imprinted domains (Figure 3.3). For instance, the Zfp264 
promoter within the Peg3 imprinted domain became hypermethylated in several benign 
specimens while the ICR retained normal DNA methylation patterns. This observation 
demonstrates the specificity of DNA methylation changes among sequence elements within 
imprinted domains during tumor progression. The observed specificity of DNA methylation 
changes within a single imprinted domain further supports the notion that epigenetic changes at 
ICRs could potentially be involved in enhancing the infiltrative potential of tumor cells as ICRs 
are only targeted during the second reconstruction of the DNA methylome.   
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To our knowledge, this is the first study to compare the epigenetic stability among ICRs 
between benign and malignant tumor cells driven by the same genomic mutation, KrasG12D. 
The results from the DNA methylation analyses of this study demonstrate that ICRs remain 
stable during the first reconstruction of the DNA methylation landscape but are targeted 
specifically by DNA hypermethylation during the second reconstruction of the DNA methylation 
landscape - a hallmark that defines the transition of benign tumor cells to malignant. Further 
investigation is required to determine whether the observed changes in DNA methylation at ICRs 
directly enhance the infiltrative potential of tumor cells. However, considering the effects that 
aberrant DNA methylation at an ICR can have on an entire imprinted domain, it is likely that 
concomitant hits to several ICRs can result in an aberrant protein environment within a tumor 
cell whereby several tumor suppressors are shut down and several oncogenes are activated. 
These dynamic changes in critical imprinted gene products may very well enhance a tumor cell’s 
ability to infiltrate tissue boundaries. Lastly, monitoring DNA methylation at ICRs may be a 
useful diagnostic in the clinical setting in determining the progression of a neoplasm.  
 
3.4 Materials and methods 
 Two mouse strains were purchased from Jackson laboratories: B6.129-Krastm4Tyj/Nci 
(LSL- KrasG12D) and STOCK Tg(MMTV-Cre)4Mam/J (MMTV-Cre) [23,24,37,38]. The LSL-
KrasG12D mice were maintained as heterozygotes and bred with homozygous MMTV-Cre mice.  
Mice weaned at 21 days post partum were separated by sex and marked by a hole punch with 
varying positions in the left ear. Ear clips were taken from the right ear for genomic DNA 
isolation and subsequent PCR analysis. Sample preparation and PCR protocols have been 
previously described [16]. Primer sets for genotyping can be found in Table 2.1.  
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Mice were monitored daily for signs of distress or weight loss equaling 15% of total body 
weight, and sacrificed according to the guidelines set forth in the IACUC protocol #16-060. 
Upon euthanasia, mice were submitted to full necropsy. Samples of squamous papilloma and 
thymic lesions were placed directly in tail lysis buffer with Proteinase K for subsequent DNA 
isolation. Detailed buffer compositions and DNA extraction protocols were previously reported 
[16]. The remaining portion of these lesions and representative samples of all other tissues were 
fixed for at least 48 hours in 10% neutral buffered formalin (Thermo Scientific, Cat. # 5725) and 
then transferred to 70% ethanol. Tissues were further processed according to standard protocols 
for hematoxylin and eosin (H&E) staining and examined by a board certified pathologist (IML).   
Combined Bisulfite Restriction Analysis (COBRA) was performed for DNA methylation 
analyses [29]. A detailed description of the protocol and reagents used for this study has been 
previously reported [16]. Table 2.1 contains detailed information pertaining to the genomic 
locations analyzed and their respective oligonucleotide bisulfite primer sets. Three independent 
technical replicates were performed for each sample and each primer set. DNA methylation 
percentages were calculated and statistically analyzed as previously described [16]. For the 
squamous papilloma panel, 28 samples were analyzed initially; however, only 15 samples were 
used for statistical comparisons based on the consistent successful bisulfite PCRs across all 
primer sets.  
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CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The distribution of DNA methylation is reshaped during the onset of cancer [1]. The 
reshaping of DNA methylation at ICRs can have profound impacts on gene regulation 
throughout imprinted domains [2]. Imprinted domains contain many genes that have oncogenic 
and tumor suppression potential whose parent-of-origin mono-allelic gene expression is 
regulated by DNA methylation at ICRs [3,4]. Therefore, improper maintenance of DNA 
methylation settings at ICRs can significantly contribute to carcinogenesis by either allowing bi-
allelic expression of proto-oncogenes or completely silencing expression of tumor suppressor 
genes. While DNA methylation changes within imprinted domains have been serendipitously 
detected in human cancer, the DNA methylation changes throughout imprinted domains has not 
been exhaustively characterized during carcinogenesis [5].  
This study provides the first report of the epigenetic stability at all of the various types of 
regulatory sequence elements within imprinted domains during the development of murine 
invasive T-cell lymphoma and benign squamous papilloma both of which were driven by the 
KrasG12D oncogenic mutation. By contrasting the epigenetic response of imprinted domains 
during the development of two fundamentally different tumors (i.e., infiltrative versus benign), 
this study was able to demonstrate that epigenetic instability within imprinted domains correlates 
with the transformation activity of tumor cells from benign to infiltrative. Furthermore, ICRs 
were identified as the main sequence element targeted for DNA methylation changes within 
imprinted domains during this transition of tumor cells. However, enhancer regions also showed 
a similar amount of DNA methylation activity, more rigorous analysis of enhancer elements is 
needed. Also, it is still unclear whether enhancer elements within imprinted domains are unique 
or if enhancer elements throughout the genome respond similarly during carcinogenesis. Overall, 
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DNA methylation at ICRs and enhancer elements within imprinted domains show high levels of 
plasticity during carcinogenesis; however, significant DNA methylation changes at enhancer 
elements may be more readily detected than at ICRs due to the normal methylation levels at 
ICRs being already at fifty percent.  
Cancer cases exponentially increase with the accumulation of mutations within cells[6]. Cells 
can tolerate a fare amount of mutation via tumor suppression mechanisms such as cell 
senescence, apoptosis, autophagy and DNA damage repair; however, disruption of one or more 
of these mechanisms can conspire with other progressive events such as epigenetic alterations to 
accelerate cell transformation towards malignancy [6]. DNA methylation changes are hallmarks 
of these cell transformations [7,8]. First, overall levels of 5mC are drastically reduced during 
transformation of normal cells to benign tumor cells and again when benign tumor cells 
transform to malignant cells [7]. Second, focal DNA hypermethylation at CpG islands housing 
promoters of tumor suppressor genes are also observed during each of these transformations. 
Thus, it can be inferred that a given gene is relevant to a specific transformation event during 
carcinogenesis based upon the timing of DNA methylation changes at its promoter. In the case of 
imprinted genes, it appears that they may promote the transformation of benign cells to 
malignant cells due to the bulk of DNA methylation changes within imprinted domains occurring 
at this time. This role during carcinogenesis fits with the function of many imprinted genes, as 
they are commonly involved with cellular processes such as apoptosis, cell cycle, angiogenesis, 
and metabolism [3,9,10,11]. Overall, this study highlights that DNA methylation changes at 
ICRs occur when benign tumor cells transform to infiltrative tumor cells.  
Although DNA methylation is a well-recognized molecular change in cancer, the signals that 
drive these molecular changes during carcinogenesis are largely unknown. The signals that 
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dictate gene expression and DNA methylation patterns during normal development may also 
choreograph the resetting of DNA methylation patterns in tumor cells. For instance, as seen 
within imprinted domains, transcription originating from an upstream promoter may signal for 
downstream CpG islands to become methylated [12]. Hypomethylation of intergenic regions 
may lead to the activitation of cryptic transcription originating from the upstream promoters; 
thus, providing a link between widespread hypomethylation and focal hypermethylation of CpG 
isalnds. Efforts thus far have identified several key players involved in carrying out the process 
of DNA methylation, which is a significant and big step toward uncovering what is ultimately 
responsible for generating the order. It will be exciting to see what future efforts will identify as 
underlying commands that dictate DNA methylation resetting. 
DNA methylation may be targeted for therapeutic interventions [13,14]. For instance, 
inhibiting DNA methylation in tumor cells with DNA-demethylating agents has been successful 
as a therapeutic intervention. While increasing the loss of DNA methylation in tumor cells seems 
counterintuitive as it increases chromosomal instability and can lead to abnormal expression of 
genes that have oncogenic potential, it also appears that reversing the hypermethylation of house 
keeping gene promoters significantly inhibits the transforming activity of tumor cells. Currently, 
two compounds that inhibit DNA methylation have been approved for use in treating 
myelodyplastic syndrome [15]. Briefly, both 5-azacytidine and 5-aza- 2-deoxycytidine bind to 
DNMTs and inhibit their activity, and thus cause genome wide hypomethylation. While this 
strategy has proven to be effective in reversing promoter hypermethylation, the non-specific 
demethylation caused by these compounds can also create problems as mentioned above. The 
advent of the clustered regularly interspaced short palindromic repeats/ CRISPR associated 
protein 9 (CRISPR/Cas9) system has provided researches with a way to potentially address the 
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pitfalls of the demethylating drugs by enabling targeted DNA methylation therapy to specific 
loci [16]. By fusing either DNMTs or TETs to a deactivated Cas9 protein, DNA methylation can 
either be written or erased at a target of interest. This system is still in its infancy however, and 
as with any new therapeutic modality, delivery is a major hurtle. Furthermore, recent reports 
have noted that this system does not work equally at different loci [17]. Nonetheless, the future 
of targeting DNA methylation for cancer therapy is bright, and it will also provide us with a 
method to better understand the dynamics of DNA methylation changes and how these changes 
contribute to carcinogenesis. 
Recently, it has been reported that the activity of transcription through CpG islands signals 
DNMTs to deposit DNA methylation [12]. This mechanism can potentially be exploited for 
targeting DNA hypermethylation to the promoter of an active gene housing an oncogenic 
mutation thereby silencing the expression of the mutation driving carcinogenesis. In theory, by 
activating transcription from an upstream promoter, RNA polymerase would then traverse the 
downstream CpG island housing the promoter driving expression of the oncogenic mutation. 
This transcriptional activity would then signal for the DNMTs to methylate the CpG island 
thereby inactivating the promoter of the oncogene. The CRISPR/Cas9 system could be used to 
deliver an engineered protein to the upstream promote and activate transcription. As a proof of 
concept, a similar approach was developed by the Segal lab to treat Angel syndrome [18]. In this 
case, a zinc finger protein was engineered to silence transcription of the Snrpn lncRNA thereby 
relieving genomic imprinting of the silenced Ube3a allele. This allowed a non-mutated form of 
Ube3a to be expressed and rescue the effects that the loss-of-function mutation on the non-
imprinted allele was causing. Advances in our ability to manipulate both genetic and now 
epigenetic information can be used to exploit mechanisms that regulate gene expression for not 
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only gaining a better understanding of normal cellular processes but also to treat human disorders 
and diseases.  
By characterizing the epigenetic response of imprinted domains during carcinogenesis, this 
study provides the community with valuable results that can help guide future research that aims 
to edit the aberrant DNA methylation within imprinted domains. Furthermore, clinicians can use 
these data as potential biomarkers during the prognosis of T-cell lymphoma progression.  
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APPENDIX A: TABLE OF GENOMIC LOCI AND PRIMERS 
 
 
 
 
 
Imprinted genes
Gene Primer Name 5'- Primer sequence -3' Genomic position PRR product length Enzymes used for COBRALoci within imprinting domain 
mNespas_ICR_bis_F GGGTGTGAGAGGTTTGGAGAGTTTATAAGA
mNespas_ICR_bis_R CCAACTAAATCTCAACCACTAACCCACTCC
mNespas_ICR_bis_c GTTTATGGGGGTTTTTGATTTTTTTATTTT
mGnas_DMR_bis_c GAGTTTTTTGAATTTGAGTTTGATTA
mGnas_DMR_bis_d CTCTCAAACTCCTAAATAATAAACT
mGnas_PRO_bis_a TAAGAAGATGGAGAAGAAGTTGTTGGAGTA
mGnas_PRO_bis_b CATCATCTTCTTCATCAATATCACTATCCCA
mPeg10_ICR_bis_a GTAAAGTGATTGGTTTTGTATTTTTAAGTG
mPeg10_ICR_bis_b TTAATTACTCTCCTACAACTTTCCAAATT
mPeg3_ICR_bis_15.2 TAGGTAGTTAATTAGGATAAGTTTGTGTAG
mPeg3_ICR_bis_16.1 CCTATTACAAAACCACCACAATAAACATCA
mPeg3_PRO_bis_11  AGAGGGTGTATGTTGTAGAGTAGTTAGGTG
mPeg3_PRO_bis_12 CATCCCTTCACACCCACATCCCATCC
mPeg3_ECR18_bis_a GGGGTTTTTTAGAATTTGTTTTATGGAGGT
mPeg3_ECR18_bis_b CTCTATCTCTTTAAATATATCCAAAACTATC
mSnrpn_ICR_bis_1 TATGTAATATGATATAGTTTAGAAATTAG
mSnrpn_ICR_bis_4 AATAAACCCAAATCTAAAATATTTTAATC
mSnrpn_ICR_bis_IF AATTTGTGTGATGTTTGTAATTATTTGG
mH19_ICR_bis_BF3 ATAGATGGTGATAGGGGAGAAAATTTA
mH19_ICR_bis_BR3 AAATTCTACAAAAAAACCATACCCTATTCTT
mH19_ECR1_bi_a TTAGGTTTGAGGTGGTAGTTTTTAG Chr7: 142,611,866-142,612,222
mH19_ECR1_bis_b TAAACTTTCCCAAAAAAACTAAACC
mH19_ECR2_bis_a GGGGATTTTTTTTTTGTATTTATAGTTG
mH19_ECR2_bis_b ACTAAAAAAAAACCTACTCTCCCTCAAACTC
mIgf2_DMR1_bis_a GTTATATTTTGATTAAATAAGGTTAGGTGAAGG
mIgf2_DMR1_bis_b CACCTCTAATCCTTATAAAACCAAATTAAACTAC
mGrb10_PRO_bis_a GGAGAGGTAATTAGTAAAGGTAGAGAG
mGrb10_PRO_bis_b ATACCAACACTCCCAAATCCCAAAC
mGrb10_ICR_bis_c GTTGTTTATTATTTGGTTGAGAGTAGA
mGrb10_ICR_bis_d TAATCCAAATAATAAACAACTCCTAC
mGrb10_E154_bis_F TTAGAGTTGTTTGGGATAAAGGAGAGTA
mGrb10_E154_bis_R TCTAAAACCCAATAACAATAACCTAACCAC
Cob1 mCobl_pro_bis_F1 GGTGGGTATYGAGTTATTTGTTTAGT
mCobl_pro_bis_R1 AATATCCACACTCCAACCTCACTACT
Ddc mDdc_pro_bis_F1 ATGTTATTTTGTTGYGTATGGTTTTGTGA
mDdc_pro_bis_R1 TAGGTTTATTTTGTTGTYGGGATTGTTTAG
mZac1_ICR_bis_a GAGTTTTTTGAATTTGAGTTTGATTA
mZac1_ICR_bis_b ATCCCAACCCAAACTAAATAACAAATC
mIg_ICR_bis_C.1 AAGTTTATGGTTTATTGTATATAATGTTGT
mIg_ICR_bis_D.1 CATCCCCTATACTCAAAACATTCTCCATTA
mDlk1_DMR_bis_c TGTGTTTTGGTTTGAGAGATTAAGTAAGAG
mDlk1_DMR_bis_d CTCACCTAAATATACTAAAAACAAATACC
mDlk1_PRO_bis_F GTGTTTTAGGGATAGGTAGTAAGGTTTGTT
mDlk1_PRO_bis_R ACCACACTCTTTAACTAAACCAATACCTAC
mGtl2_DMR_bis_a ATTATGTTTAATTGGATTTATTAATGGTG
mGtl2_DMR_bis_b CTAATCTAACAAACCAAAAACCATTTACAC
mIgf2r_ICR_bis_a TATTTTGGGGAATTGAGGTAAGTTAGGGTT
mIgf2r_ICR_bis_b ATTTTCTTATAACCCAAAAATCTTCACCCT
mRassfrf1_ICR_bis_FK GGAATTTTGGGGATTTTTTAGAGAGTTTATAAAGT
mRassfrf1_ICR_bis_RK CAAAAACAACAATAATAACAAAAACAAAAACAATAT
Mest mPeg1/Mest_bis_OF GATTTGGGATATAAAAGGTTAATGAG
mPeg1/Mest_bis_OR TCATTAAAAACACAAACCTCCTTTAC
N/A N/A N/A N/A N/A N/A Gatm, Sfmbt2
N/A N/A N/A N/A N/A N/A Nnat, Blcap
mFhit_PRO_bis_c GGAGTTAAGTTTAAGTGGAATAGAATGTG
mFhit_PRO_bis_b AACTATTCAAAAGTAGCCACAATGACACCT
mMgmt_PRO_bis _F GGTTTGGAAGAAGAGGTTTGTTTTAGGAAT
mMgmt_PRO_bis_d TCACCAACTTACAAACTACAAACAACAAC
mApc_PRO_bis_F GAAAGGTGAGTAGGTTAGAGATTTAGGATT
mApc_PRO_bis_R CTAAAAAAACCACTCCTCACTCCACCTTCC
mGstp1_PRO_bis_F TTTAGTATAAAGTGGAAGGGAGTTGGATAT
mGstp1_PRO_bis_R CAGAGTGGTACACTTTCCCACCCCATCTCC
mMlh1_PRO_bis_F CTCAGCTCTCAGAAATGAGCCAATAGGAAG
mMlh1_PRO_bis_R TGTGCATAATGGGAAACCAGCCTGGCAC
mMsh2_PRO_bis_F GTTTTTGGAAGGTTTGTAAGGTTGTAGAAG
mMsh2_PRO_bis_R CTCCACACCAACACCACTAAAACACAAAAC
mRassf1a_PRO_bis_F GGGGTTTTTTGAAAGGGTTTATTTTTGTGT
mRassf1a_PRO_bis_R GATCATCACAACTGACCAGCCCTCCACTGC
mChek2_bis_F TAAAAGTTTTTTTTTTAGGAATTTTGTTAG
mChek2_bis_d AATACAAACTCCACCCTCAACCAATCAA
Genotyping
Kras Kras F1 GTCTTTCCCCAGCACAGTGC
Kras Fcass AGCTAGCCACCATGGCTTGAGTAAGTCTGCA
Kras R1 CTCTTGCCTACGCCAC CAGCTC
MMTV-Cre MMTV-Cre F CTGATCT GAGCTCTGAGTG
MMTV-Cre R CATCACTCGTTGCATCGACC
Copg2, Copg2os2, Nap1l5, Klf14, Mest, Copg2os1, Mir335
356 bp Taq1
BSTU1346 BPChr7: 142,571,477-142,571,823
Tumor suppressor genes
chr11:11,856,745-
11,857,746 
304 bp Taq1
Chr9: 89,879,621-89,880,021Rassgrf1 Rasgrf1, Mir184
Igf2r Slc22a3, Slc22a2, Airn, Igf2r, Pde10aChr17:12741407-12741688
Nespas, Gnas
Grb10
chr11:12364538-
12365200 
335 bp Bstu1, Taq1
Ddc, Grb10, Cobl, Zrsr1, Commd1
chr11:11797984-11798367 381 bp Taq1, HpyCHIV
Chr7: 60004987-60005420420 bp Bstu1, Hha1 Snrpn, Mkrn3, Mkrn3os, Ipw, Ube3a, Ndn, Snurf, Mag
el2, Snord116, Snord64,   Snord115, Peg12, Atp10a
Chr11:12025419-
12025726
Chr11:12036436-12036697
Nespas
Peg10
Snrpn
Chr6: 4747895-4748446 Sgce, Asb4, Dlx5, Calcr, Peg10, Ppp1r9a, Pon2, Pon3,
 Tfpi2, Casd1
Chr2: 174294993-174295604
Peg3
Chr7: 6730213-6730667
Chr7: 6729538-6729883
Hpy99I
561 bp
257 bp
469 bp
Hinf1
Cla1
354 bp
362 bp
285 bp
Mlu1
MluI
FokI
HhaI
FokI
Hpy99I
Hpy99I
Bstu1
690 bp Mbo1, Taq1
281 bp
400 bp
Chr18: 34220741-34221103 
Chr7: 136894337-136894691
Chr2: 174284913-174285242
F/R: 611 bp; c/R: 328 
bp      (use c/R for 
sequencing)
Taq1, Hph1, Mbo1
3 8 bp Taq1, Bstu1, Fok1
Taq1
Hpa1
Taq1, Hph1
Hha1, Hph1551 bp (sequencing did 
not work)
345 bp
454 bp
421 bp
262 bp
Chr14: 9550402-11162035
307 bp
413 bp
307 bp 
250 bp
345 bp
425 bp
Chr10:13090541-13090791
Chr7: 6913709-6914130
Chr7: 142581719-142582121H19
Igf2
Peg3, Zim1, Usp29, Zim3, Zfp264, Zim2
Ins2, H19, Igf2, Ascl2, Cdkn1c, Phlda2, Kcnq1, Igf2os, 
Cd81, Tssc4,    
 Osbpl5, AF313042, Nap1l4, Th, Tspan32,Slc22a18, 
Tnfrsf23, Dhcr7, Kcnq1ot1
Chr7: 142665283-142665695
Mbo1, Hpy991, Fok1
Gtl2
Zac1/Plagl1
Chr12:109459472-109459897
Chr12:109528222-109528567 Bstu1, Mlu1, Mbo1, HpyCHIV
Taq1, Bstu1, HpyCHIV
Hha1, Hph1
HpyCHIV
Dlk1, Ig,Meg3/Gtl2, Rtl1, AF357428, AF357341, Dio3, 
Mir376b, Mir154, Mir337, Mir433, Mir411, Mir127, Mir3
80,Mir370, 
Mir136, AF357426, Mir134, Mir410, AF357425, Mir434, 
Mir431, Rian, Begain
411 bpChr12: 109542677-109543088
Chr12: 109452874-109453320446 BP Hpy1881, Hha1
Ig
Msh2
Rassf1a
Chek2
281 bp Bbs1
Gnas
Chr2: 174328782-174329063
Taq1
542 bpChr9: 111228228-111271608
Chr14: 100815494-100815707
Chr9: 107551555-107562263
Chr17: 87672330-87723713
213 bp
Chr: 19: 4035411-4037912
Bstu1, Hph1
Fhit
Mgmt
Apc
Gstp1
Mlh1
Zac1/Plagl1
Dlk1
Chr6: 30,736,677-30,737,3 7
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